Study REP0112 –Amendment  No. 1  Reparixin in IAT  Page 1 of 4 
 
 
 
 
 
AMENDMENT  No. 1  
To the CLINCIAL STUDY PROTOCOL version No. 1 – Final 11 October 2013 
APPLICABLE TO SITE No. 01 ONLY 
[Schulze Diabetes Institute; University of Minnesota Medical School] 
 
 
Study Number:  REP0112 
 IND Number:   [ADDRESS_544414]:  Reparixin  
 
 Title:  A phas
e 2/3, multicent er, randomized, double-blind, placebo-controlled, 
parallel assignment study to assess the efficacy and safety of reparixin in pancreatic islet auto -transplantation.  
    Amendment No. 1 Version – Date  Version No. 1 – final 18 Jul
 y 2016   
   
STATEMENT OF CONFIDENTIALITY  
Information in this amendment and accompanying documents contains privileged or 
confidential informati
on that is the property of Dompé farmaceutici s.p.a. It is understood 
that the information will not be used, divulged, or published without prior written consent of 
Dompé, except to the extent such disclosure is required by [CONTACT_774]. 
 
      
NOTES :  
This Amendment does not result in a change to either the CRF or the ICF. 
 
Version No. 1 – final 18  July 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
_____________________________ ________ _________ __
_____________________________ ________ _________ __
____________________________________________________

Study REP0112 –Amendment  No. 1  Reparixin in IAT  Page 2 of 4 
 
PROTOCOL AMENDMENT APPROVAL SIGNATURES  
 
SPONSOR :  
Medical Expert  
 
[INVESTIGATOR_7496]:   _____________________________  Date:   ______________________  
Pi[INVESTIGATOR_430355], MD – Development Director  
  
 
 
 
C
LINICAL CENTRE :  PRINCIPAL INVESTIGATOR  [PRIMARY INVESTIGATOR ] 
I have read study protocol REP0112 “A phase 2/3, multicenter, randomized, double-blind, 
placebo -controlled, parallel assignment study to assess the efficacy and safety of reparixin in 
pancreatic islet auto -transplantation”.  
 
Name [CONTACT_789]:  [INVESTIGATOR_430356], MD 
 Signature:   _____________________________  Date:   ______________________  
 
 
  
Version No. 1 – final 18  July 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
_____________________________ ________ _________ __
_____________________________ ________ _________ __
____________________________________________________

Study REP0112  Reparixin in IAT  Page 1 of 68 
 
 
 
 
  
CLINICAL STUDY PROTOCOL - CONFIDENTIAL  
 
  
Study Number:  REP0112 
 IND Numb er:  
[ADDRESS_544415]:  Reparixin  
 
 Title:  A phas
e 2/3, multicenter , randomized, double-blind, placebo -controlled, 
parallel assignment  study to assess the efficacy  and safety of reparixin in 
pancreatic islet auto-transplant ation . 
  Protocol Version  – Date  Version  No. 2 – Fi n
 al 18 July 2016 
APPLICABLE TO SITE No. 01 ONLY 
[Schulze Diabetes Institute; University of Minnesota Medical School] 
  
This protocol version results from revision of pr otocol version No. 1 (Final, 11 October 2013) 
according to Amendment No. 1 (final 18 July 2016).  
 
STATEMENT OF CONFIDENTIALITY  
Information in this protocol and accompanying documents contains privileged or confidential 
information that is 
the property of Dompé s.p.a. It is understood that the information will not 
be used, divulged, or published without prior written consent of Dompé, except to the extent 
such disclosure is required by [CONTACT_774]. 
 
Version No. 2 – final 18Jul [ADDRESS_544416] INFORMATION 
 
SPONSOR  Dompé s.p.a. [Dompé] 
 Via C
ampo di Pi[INVESTIGATOR_5829]; 6710 0 L'Aquila, Italy  
 Milan Offices: Via S. Lucia 6 , [ZIP_CODE] Milan, Italy 
 Phone: 
[PHONE_8945]; Fax: [PHONE_8946] 
 
 Medical Expert  [CONTACT_25715][INVESTIGATOR_430357] , MD - Development Director  
  Dompé s.p.a. - Milan Offi ces;  
  Direct line: [PHONE_8947] ; Mobile : +39 [PHONE_8937] 
  e-mail:  
  Clinical Trial M
anager  Luisa Daffonchio, P hD - Clinical Development Manager  
  Dompé s.p.a. - Milan Offi ces;  
  Direct line: [PHONE_8948];  
  e-mail: luisa. [EMAIL_8191] 
  Pharmacovigilance [CONTACT_430469], QPPV  
  Dom 
pé s.p.a. - Milan Offices  
  Direct line: [PHONE_8949]; Mobile: [PHONE_8950] 
  Fax: [PHONE_8951] 
  e-mail:  
  
 
CLI
NICAL RESEARCH  inVe
ntive Health Clinic al [inVentive]  
ORGANIZATION  504 Carnegie Center;  Princeton, NJ [ZIP_CODE], [LOCATION_003] 
 Phone: +[PHONE_8938]; Fax: +[PHONE_8939] 
 
 Project Manager  Fiona Wingrave - Manag er, Clinical Research  
  [ADDRESS_544417]; Burlington, ON  L7L 6G4, 
  Canada 
  Phone: +[PHONE_8940]; F
ax: +[PHONE_8941]  
  e-mail: fiona.wingrav [EMAIL_8192]  
 
 
 
 INVESTIGATIONA L 
SITES   
Primary Investigat
or 
Melena Bellin, MD ; Assistant Profes sor, Pediatric Endocrinology and Diabetes 
Schulze Diabetes Institute; Univ ersity of Minnesot a Medical School 
MMC 404, [ADDRESS_544418] SE - Minneapolis, MN [ZIP_CODE] Phone:  [PHONE_8942] or [PHONE_8943] 
Fax:  612 -624-0420 (SDI), [PHONE_8944] (P ediatric  Endocrinology)
  
Full list of investigational sites will be kept in the Trial Master  File. Updated versions , if any, will be 
filed chronologically.  
  
CENTRALIZED LABORATORIES    
List of centralize
d laboratories will be kept in the Trial Master Fil e. Updated versions, if any, will be 
filed chronologically.   
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
_____________________________ ________ _________ __
_____________________________ ________ _________ __
____________________________________________________

Study REP0112  Reparixin in IAT  Page 3 of 68 
 
PROTOCOL APPROVAL SIGNATURES 
 
SPONSOR :  
Medical Expert  
 
[INVESTIGATOR_7496]:   _____________________________  Date:   ______________________  
Pi[INVESTIGATOR_430355], MD - Development Director  
  
Clinical Trial Manager  
 Signature:   _____________________________  Date:   ______________________  
Luisa Da
ffonchio, PhD – Clinical Development Manager  
 
 
 
CLINICAL CENTRE :  PRINCIPAL INVESTIGATOR  [PRIMARY INVESTIGA TOR] 
I have read study protocol REP0112 “A phase 2/3, multicenter, randomized, double -blind, 
placebo -controlled, parallel assignment study to assess the efficacy and safety of reparixin in 
pancreatic islet auto -transplantation”.  
 
Name [CONTACT_115278]:  Melena Belli n, MD  
 Signature:   _____________________________  Date:   ______________________  
 
  
Version No. 2 – final 18Jul [ADDRESS_544419] 
ADMINISTRATION  ......................................................................................................... 28  
6.3. CRITERIA FOR SCHEDUL E ADJUSTMENT/DOSE -MODIFICATION/ 
DISCONTINUATION OF INVESTIGATIONAL PRODUCT  ........................................ [ADDRESS_544420]  ..................................................... 28  
Version No. 2 – final 18Jul [ADDRESS_544421]  ........................................................... 38  
8.3.3.  Severity of AEs  .................................................................................................................. 38  
8.4. SERIOUS ADVERSE EVEN T REPORTING  .................................................................. 39  
8.4.1.  Reporting Procedure for Investigators to Dompé (or designee)  ........................................ [ADDRESS_544422] (IRB)  ............................................................................. 47  
10.2. INFORMED CONSENT  ................................................................................................... 47  
10.3. CONFIDENTIALITY  ....................................................................................................... 48  
Version No. 2 – final 18Jul [ADDRESS_544423]  .................................................................................................................. 49  
11.3. DATA MANAGEMENT  .................................................................................................. 49  
11.4. DOCUMENTATION REQUIR ED PRIOR TO INITIATION OF AND DURING 
THE STUDY  ..................................................................................................................... 49  
11.5. ESSENTIAL DOCUMENT R ETENTION  ....................................................................... 50  
12. STUDY MANAGEMENT  ............................................................................................... 51  
12.1. REGULATORY BODY APPROVAL  .............................................................................. 51  
12.2. STAFF INFORMATION & RESPONSIBILITIES  .......................................................... 51  
12.3. MONITORING  ................................................................................................................. 51  
12.3.1.  Access to records  ............................................................................................................... 51  
12.4. AUDIT AND INSPECTION  ............................................................................................. 51  
12.5. DATA MONITORING COMM ITTEE  ............................................................................. 52  
12.6. PROTOCOL DEVIATIONS/AMENDMENTS  ................................................................ 53  
12.7. DISCONTINUATION OF THE STUDY  ......................................................................... 53  
12.8. PUBLICATIONS  .............................................................................................................. 53  
13. REFERENCES  ................................................................................................................ 54  
14. APPENDICES  .................................................................................................................. 56  
14.1. APPENDIX 1 – CUMULATIVE SUMMARY OF ADVERSE DRUG 
REACTIONS1.................................................................................................................... 56 
14.2. APPENDIX 2 - PACKAGING AND LABELING DETAILS .......................................... 58  
14.3. APPENDIX 3 - STUDY DRUG INFUSION RATE BY [CONTACT_430403]  ..................... 60  
14.4. APPENDIX 4 - STUDY FLOW CHART  ......................................................................... 62  
14.5. APPENDIX 5 - ACCEPTABLE TIME WINDOWS FOR ASSESSMENTS/ 
PROCEDURES  ................................................................................................................. [ADDRESS_544424]  ............................................................................................... 66  
14.6.5.  β-score calculation  ............................................................................................................. 67  
14.7. APPENDIX 7 – SAMPLE DIARY CARD  ....................................................................... 68  
 
Version No. 2 – final 18Jul [ADDRESS_544425]  Aspartate Aminotransferase  
AUC  Area Under the Curve  
AUC 0-t Area under the plasma concentration -time curve from time zero to time t (time of last quantifiable 
plasma concentration) of reparixin  and metabolites  
AUC 0-∞ Area under the plasma concentration -time curve from time zero to infinity of reparixin and 
metabolites  
BP Blood Pressure  
C Degrees Celsius  
CL Clearance of reparixin and metabolites  
CLcr  Calculated Creatinine Clearance (Cockcro ft - Gault formula)  
Cinitial Plasma concentration of reparixin and metabolites just prior to the end of administration  
Cmax  Maximum Plasma Concentration  
CMED  Concomitant Medication  
cmH 2O Centimeters of Water  
CPB  Cardiopulmonary By[CONTACT_430404]  C-reactive Protein  
Css Steady State Concentration  
CXCL8  CXC ligand 8 [formerly interleukin (IL) -8] 
ddPCR  Droplet Digital PCR  
DMC  Data Monitoring Committee  
g Grams  
GCP  Good Clinical Practice  
HbA1c  Glycated hemoglobin  
HR Heart rate  
kg Kilogram  
IAT Islet Auto -Transplantation  
ICH International Conference on Harmonization  
IRB Institutional Review Board  
IEQ Islet Equivalent  
IND Investigation New Drug  
INR International Normalized Ratio  
ITT Intent to Treat  
i.v. Intravenous  
LD [ADDRESS_544426]  
ng Nanogram  
NGSP  National Glycohemoglobin Standardization Program  
NSAID  Non Steroidal Anti -Inflammator y Drug  
PI[INVESTIGATOR_430358]  
p.o. per os (taken by [CONTACT_1966])  
PTT Partial Thromboplastin Time  
SAE  Serious Adverse Event  
s.c. Subcutaneous  
t½ Elimination half life  
tmax  Time of maximum plasma concentratio n of reparixin and metabolites  
TPN  Total Parenteral Nutrition  
U-CRA  Unblinded -CRA  
ULN  Upper Limit of Normal  
Vz Volume of distribution of reparixin  
XDP  Fibrin Degradation Products  
μg Microgram  
λz Terminal phase rate constant reparixin and metabolites  
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 8 of 68 
 
1. STUDY SYNOPSIS AND O VERALL DESIGN  
 
Study title  
A phase 2/3, multicenter, randomized, double -blind, placebo-controlled, parallel assignment study to 
assess the efficacy and safety of reparixin in pancreatic islet auto -transplantation . 
Study Number  REP0112          [ US IND #  117390] 
 
Study 
period  Projected  starti n g date (first -patient-in): December [ADDRESS_544427] etion of patient accrual (last-patient- in): March 2015 
 Projected stu dy  end date (last -patient -last-visit): March 2016 
 
Study design  
The study will be a phase 2/3, multicenter, doubl e-blind, parallel assignment study.  It will involve 100 
adult recipi[INVESTIGATOR_430359]- hepatic pancreatic Islet Auto-Transplant ation  (IAT).   
Patients will be randomly ( 1:1) assigned to receive either reparixin treatment (continuous i.v. infusion 
for 7 days – treatment group) or placebo (control group).  The two groups will be balanced within 
centres.  Recruitment will be competitive among the stu dy sites, until the planned number of patients 
is enrolled.   
 
Objectives/endpoints  
The objective of this clinical trial is to assess whether repa rixin  leads to improved transpl ant outcome 
as measured by [CONTACT_430405]- independent patients  follo wing  IAT.  The safety of reparixin  
in the specific clinical setting will be also evaluated.  
 
Efficacy endpoint s will be :  
• The proportion of insulin- independent patients following IAT [ Primary endpoint . time frame: 
day 365+ 14 after the transplant].  
• Area Und er the Curve ( AUC ) for the serum C- peptide level during the first 4 hours of an MMTT, 
normalized by [CONTACT_430406] ( IEQ)/kg [Time frame: day 75 +14 and 365+ 14 after 
the transplant].  
• Average daily insulin requirements [time frame: day 75 +14 and 365+14 after the transplant]. 
• Basal (2 basal samples in the range  between -20 to 0) to 240 min time course of glucose, C -
peptide and insulin  derived from the MMTT  [time frame: day 75 +14 and 365+ 14 after the 
transplant].  
• β-cell function as assessed by β-score [time frame: day 75 +14 and 365+ 14 after the transplant].  
• The proportion of patients with an HbA1c <6.5% [time frame: day 365+14 after the transplant]. 
• Cumulative number of severe hypoglycemic events [time frame: from day 75+14 to day 365+14 
after the transplant].  
• The proportion of patients with an HbA1c <6.5% at day 365+14 AND are free of severe 
hypoglycemic events from day 75+14 to day 365+14 inclusive [time frame: day 365 +14 and from 
day 75+14 to day 365+14 after the transplant].   
 
Safety endpoints will be :  
• Incidence and severity of Adverse Events and Serious Adverse Events [time frame: throughout the study up to day 365+14 after the transplant].  
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 9 of 68 
 
• Standard laboratory tests including hematology (hematocrit, hemoglobin, red blood cells, 
platelets, white blood cells, differential white blood cells count), clinical chemistry (sodium, potassium, serum creatinine, blood urea nitrogen, total bilirubin, a lanine aminotransferase  (ALT ), 
aspartate aminotransferase ( AST ) and coagulation ( International Normalized  Ratio  (INR), partial 
thromboplastin time (PTT))  [time frame: pre -transplant hospi[INVESTIGATOR_430360] -transplant 
hospi[INVESTIGATOR_2345]].  
• Vital signs, i.e. blood pressure ( BP) and heart rate (HR)  [time frame: pre- tra
 nsplant hospi[INVESTIGATOR_430361] -transplant hospi[INVESTIGATOR_17399] l discharge].  
• ALT/AST, INR/PTT, fibrin degradation products ( XDP s), C-reactive protein (CRP ) [time frame: 
all daily from day 1 up to day 7 after the transplant; ALT/AST also on day 75+14 after the 
transplant].  
• Weight loss from pre- transplant value [time frame: day 75 +14 and 365+ 14 after the transplant].  
• Serum  level of albumin and pre -albumin (absolute and change from pre -transplant value) [time 
frame: day 75 +14 and 365+14 after the transplant]. 
• Severity of steatorrhea [time frame: day 75 +14 and 365+ 14 after the transplant].  
• Malnutrition risk (poor prognosis, significant risk, increased risk, normal) acco rding to pre -
albumin level [time frame: day 75 +14 and 365+14 after the transplant].  
• Cumulative number of epi[INVESTIGATOR_430362] ( documented symptomatic; 
asymptomatic) [time frame: from day 75+14 to day 365+ 14 after the transplant].  
• Cumulative number of diabetic ketoacidosis -related events [time frame: from day 75+14 to day 
365+ 14 after the transplant].  
 Exploratory endpoints will be
: 
• Time course of inflammatory chemokines/cytokines as assessed by [CONTACT_430407]8, CCL2 
(MCP -1), CCL3, CCL4, CXCL10 (IP -10), CXCL9 (MIG), IL -6, IL -10, INF-γ, TNF -α, and IL-1β 
[time frame: pre -infusion hospi[INVESTIGATOR_063] (2 basal samples collected 6 to 24 hrs apart; both 
samples will be obtained before surgery and before Investigational Product administration  is 
started ) and 6, 12, 24, 72, 120 and 168hrs after the end of islet infusion].  
• Proportion of patients who are randomized but do not receive IAT [time frame: transplant day] . 
• Time course of serum mi croRNA- 375 (miR-375)  [time frame: pre -infusion hospi[INVESTIGATOR_105904]  
(sample will be obtained before surgery and before Investigational Product administration  is 
started ) and 6, 12, 24, 72, 120 and 168hrs after the end of islet infusion]. 
 
Pharmacokinetic endpoints will be : 
• Plasma levels of reparixin (total and unbound ) and relevant metabolites (DF2243Y and 
ibuprofen) [time frame: post -operative day 1, 3, and 5 (steady state)  in all patients ; just prior to, 
and then at 1, 3, 5, 6, 8, and [ADDRESS_544428] 20 -24 patients]. 
 
Number of patient s 
The goal of this study is to reach a tota
l of 100 patients who are randomized and receive IAT after 
total or completion pancreatectomy. 
 Inclu
sion/exclusion criteria  
Patients aged > 18 years given written informed consent who are eligible for an IAT foll owing total (or 
completion) pancreatectomy will be included in this study. 
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 10 of 68 
 
Recipi[INVESTIGATOR_22880] a previous IAT (if completion pancreatectomy) as well as p atients undergoing total 
pancreatectomy due to pancreatic cancer or pancreatic benign diseases (e.g. pancreat ic pseudocystis, 
insulinomas, etc .) will be excluded.   
Patients who have inadequate renal reserve (calculated creat inine clearance < 60 mL/min according to 
the Cockcroft -Gault formula), hepatic dysfunction (increas ed ALT/AST > 3 x upper limit of normal or 
increased total bilirubin above upper limit of normal at local laboratory , except patients with Gilbert’s 
syndrome), a preoperative International Normalized Ratio ( INR) > 1.5 or any known coagulopathy , 
hypersensitivity to  ibuprofen or to more than one non  steroidal anti -inflammatory drug  or to more than 
one medication belonging to the class of sulfonamides (e.g. sulfamethazine, sulfamethoxazole, 
sulfasalazine, nimesulide or celecoxib  - hypersensitivity to sulphanilamide antibiotics alone , e.g.  
sulfamethoxa
zole, does not qualify for exclusion) will be also excluded . 
Also, patients w
ill be excluded from study participation if they have concurrent sepsis (as per positive 
blood culture(s) a
nd/or fever associated with other signs of systemic sepsis syndrome), have received a 
treatment with systemic steroids  in the 2 weeks prior to enrolment (except for the use for physiological 
replacement only), or any investigational agent (including any anti -cytokine/chemokine agents) or any 
immune modulators in the [ADDRESS_544429]  pre-existing diabetes or evidence of 
impaired β-cells function (pre-operative fasting blood glucose >115 mg/dL and/or a HbA1c > 6.5%) or 
require treatment with any anti -diabetic medication (e.g. insulin, metformin, etc) with in the [ADDRESS_544430] evidence of pre -
operative portal hypertension (clinical history and abdominal/liver imaging by [CONTACT_430408]). 
Pregnant or breast -feeding women  or p atients unwilling to use effective contraceptive measures 
(females and males) will not participate in the study. 
 
Investigational Product  
The investigational drug will be reparixin  or matching placebo.   Reparixin will be administered as a 
continuous i.v. infusion into a (high flow) central vein at a dose of 2.772 mg/kg body weight/hour for 
7 days  (168h rs), starting approximately 12hrs (6-18 hrs) before pancreatic  islet infusion.   Placebo 
(0.9% w/v sodium chloride solution) will be infused  at matching vo lume/rate.   
 
Procedures  
Each patient will be involved in the study for a [ADDRESS_544431]- transplant 
visits scheduled at day 7 5+14 and 365+ 14 after the transplant.  
 Statistics  
All patient data collected on the CRF and on the Diary will be listed by [CONTACT_4676], treatment group and 
centre.  The data w
ill be presented in the Clinical Study Report.   
Appropriate descriptive statistics w ill be produced, acc ording to the variable.  
For the primary efficacy endpoint, the proportion of insulin- independent patients following IAT over 
the time frame of day 365+ 14 after the transplant, the differences in proportions will be assessed using 
the Pearson Chi -square statistic, stratified by [CONTACT_430409]: < 2500 IEQ/kg vs. 2500 -
5000 IEQ/kg vs. > 5000 IEQ/kg.   
A Statistical Analysis Plan will be issued describing details of all the statistical methods and analysis to be applied to trial results.  Any deviations from the original statistical plan will be described in the 
Clinical Study Report. 
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 11 of 68 
 
2. BACKGROUND INFORMATI ON 
Reparixin is a specific inhibitor of CXC ligand 8 [ CXCL8 ; formerly interleukin (IL) -8] biological 
activity, stemming from a program of drug design of molecules intended to modulate chemokine 
action.  
Reparixin is the first low molecular  weight blocker of CXCL8 biological activity in clinical 
development.  Relevant pre -clinical, toxicological and phase 1 and 2 clinical data are  summarized 
below.  Please also refer to the Investigator’s Brochure for more detailed information.  Reparixin (formerly repertaxin) was granted  orphan drug designation for the
  “prevention of delayed 
graft function after (solid) organ transplantations” by [CONTACT_430410] 2001 and by [CONTACT_430411] 2003.  More 
recently orphan drug designation has been granted in EU (Septemebr 2011) for the “prevention of 
graft loss in pancreatic islet transplantation” and in the US ( September 2012) for the “prevention of 
graft loss in islet cell transplantation”.  
2.1. RELEVANT NON- CLINICAL PHARMACOLOG Y 
Reparixin is in vitro  a potent and specific inhibitor of CXCL8 biological activity.  In vitro  chemotax is 
experiments have shown that reparixin  inhibits CXCL8 -induced chemotaxis of human 
polymorphonuclear leukocytes (PMN ) in the low nanomolar range.  Studies to elucidate the 
mechanism of action have shown that reparixin  is a non -competitive allosteric inhib itor of the CXCL8 
receptors CXCR1 and CXCR2.  Interaction of reparixin  with CXCL8 receptors inhibits the 
intracellular signal transduction events activated by [CONTACT_430412]8 to CXCR1 and CXCR2 
[Bertini, 2004; Allegretti, 2005].  
In vivo , reparixin preven ted PMN infiltration into the transplanted kidney and reduced creatinin levels 
in a rat model of kidney transplantation.  Similarly, in a rat model of lung transplantation, reparixin 
improved isolated graft oxygenation, decreased pulmonary oedema, and significantly reduced 
neutrophil infiltration into transplanted lungs.  Moreover, reparixin prevented PMN infiltration and 
tissue damage in other animal models of ischemia/reperfusion  injury of liver, brain, intestine, heart 
and spi[INVESTIGATOR_1831].  In these models, in vivo inhibition of PMN recruitment ranged from 40 to 90%, and 
inhibition of tissue damage ranged from 50 to 80%.  Efficacy was seen in all models at reparixin dose 
of 9.90 mg/kg [Bertini, 2004; Cugini, 2005;  Souza, 2004; Cavalieri, 2005; Garau, 2005; Villa, 2007; 
Gorio, 2007].  
More recently, reparixin  lysine salt was evalua ted in different  mode ls of intrahepatic pancreatic islet  
transplantation  in mice, which include syngeneic and allogeneic settings.  Reparixin was administered 
by s.c. continuous infus ion for 7 or 14 days starting from day -1 of islet transplantation .  A dose of 
5.28 mg/kg/hour was administered in all experiments .  Reparixin was able to significantly improve 
islet engraftment, as demonstrated by [CONTACT_430413] e to 
gain non-fasting blood glucose levels less than 200 mg/dl (normo- glycaemia) in marginal mass 
syngeneic islet transplantation model.  In the fully mismatched allogeneic model, reparixin not only 
protect ed islets f rom early graft failure , but was also able to increase the time to rejection , as shown by 
[CONTACT_447]- transplant prolongation of normo -glycaemia.  Graft function was indefinitely prolonged in 
20/30% of mice treated with reparixin and rapamycin, suggesting possible tolerance induc tion.  In 
parallel, reparixin treatment reduced intrahepatic infiltration of PMNs, macrophages , T helper and 
dendritic cells [Citro, 2012a].  
Reparixin also delay ed the onset of diabetes induc ed in mice by [CONTACT_430414].  
Also, mice treated with reparixin retained  a better glyc emic control ( lower glyc emic levels) even after 
diabetes development [ Citro, 2012b ]. 
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 12 of 68 
 
2.2. A SUMMARY OF TOXICOLOGY DATA  
Reparixin was tested for toxicity in rodent and non- rodent animal species after single and repeat ed i.v. 
doses.  The repeated dose administration studies were conducted by i.v. continuous infusion, 
according to the intended  human administration route.  
The general toxicological profile of i.v. reparixin , in the studies  conducted to date, is characterized by 
a low toxicity after single or repeated dose administrations in rats (LD 50 = 229.68 mg/kg i.v.; 660.00 
mg/kg/day as No Observed Adverse Effect Level from 4 weeks studies) and mice (401.94 mg/kg i.v.).  
Continuous i.v. administration to dogs for 2 weeks resulted in a safe dose of 39.60 mg/kg/day. 
Continuous i.v. infusion of reparixin to the male and fem ale rat at dose levels of up to 660.00 
mg/kg/day did not have any significant adverse effects on mating performance and fertility.  
Reparixin poses no genotoxic hazard for humans. 
Reparixin lysine salt, at doses in excess of those intended to be used in humans, has a safe 
pharmacology prof
ile in the renal, cardiovascular and respi[INVESTIGATOR_430363].  
The local tolerability of reparixin  lysine  sa lt was assayed in the rabbit ear lateral vein.  The compound 
was well tolerated in concentrations up to 4.95 mg/mL (1 mL/kg) infused over a minute. 
In order to provide evidence of the safety of DF2243Y, the main metabolite of reparixin  excre ted in 
urine  in humans, safety pharmacology and toxicity studies have been perform ed at doses [ADDRESS_544432] METABOLISM  
PK stud ies by i.v. injection revealed that reparixin is very rapi[INVESTIGATOR_430364] (t 1/2 
0.5-3hrs and 1.0-1.5hrs , respectively) whereas elimi nation is slower in dogs (12 -28hrs ).  The PK of 
reparixin was linear in rats and in dogs but linearity was less evident in humans.   
Reparixin undergoes complete metabolism (oxidation + conjugation) in all the species tested. The in 
vitro  human hepa
tic, phase I metabolism of reparixin is catalysed by [CONTACT_097]2C9 and to a lesser extent by 
[CONTACT_097]2C19.  DF2243Y, DF2188Y, methanesulfonamide and ibuprofen are the metabolites detected in 
human plasma and urine, with DF2243Y being the major metabolite.  Exposure to ibuprofen after 
administration of reparixin 2.77 mg/kg/ h for 48hrs  (the highest dose tested in humans) was simil ar or 
lower than that obtained after a standard therapeutic single dose of ibuprofen (300mg). 
Due to extensive metabolism, unchanged reparixin was poorly or not excreted into the urine of rat, 
dogs and humans so that
 the PK profile of reparixin is not infl uenced by [CONTACT_368459].   
In vitro  protein binding of [14C]-reparixin showed that reparixin is highly bound (approximately 99%) 
to plasma proteins in rats, dogs, rabbits, cynomolgus monkeys and humans.  Albumin is likely to be the 
major binding protein  in plasma in all species, accounting for 99.2% in humans.  
Reparixin has some potential in vitro  for a non -competit ive inhibition of the human hepatic enzyme 
CYP3A4 that is involved in the metabolism of cyclosporine A, tacrolimus and rapamycin.  However, since inhibition is evident at concentration far higher than the free plasma concentration of reparixin at steady state in humans, it is predicted that the clinical relevance of such inhibition is remote.  Indeed, 
reparixin does not affect to a clinically relevant extent the activity of CYP3A4 and CYP2C9 (enzyme 
involved in reparixin metabolism), as revealed by [CONTACT_430415] (probe substrates for these enzymes) was evaluated in healthy subjects receiving sing le 
oral doses of the probes alone or in combination with reparixin.   
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 13 of 68 
 
2.4. A SUMMARY OF CLINICAL  DATA  
Clinical development includes phase 1 pharmacokinetics, tolerability and pharmacodynamic studies 
and 2 phase 2 studies conducted in lung and kidney transplant  patients.  An independent study was 
also carried out in cardiopulmonary by[CONTACT_6476] ( CPB) patients.    
To date, a total of [ADDRESS_544433] metabolism in humans  
Three  phase 1 PK/safety studies were performed which included 30min to 48h i.v. infusion of 
ascending doses in healthy male subjects and 6h i.v. infusion of a selected dose in male and female 
subjects with normal to severely impaired renal function [REP0101; REP0102; REP0203 ].  An 
additional interaction study was also conducted in healthy subjects [ REP0103 ].  PK results are 
discussed in  paragraph 2.3.  
2.4.2. Efficacy  
In the first US -Canada phase 2 study  [REP0104 ], 101 patients (46 on reparixin, 55 on placebo) 
undergoing single or bilateral lung transplant were included in the intent to treat (ITT) and safety 
population out of 114 enrolled.  The patients were randomized to receive 48h i.v. continuous infusion 
(loading: 4.488 mg/kg/h for 30min, maintenance: 2.772 mg/kg/h for 47.5h rs) of either reparixin or 
placebo starting a few hours before the transplant.  The study failed to show any statistically significant difference between the reparixin and placebo groups in the primary efficacy variable 
(PaO
2/FiO 2 ratio) and in any of the secondary efficacy variables assessed up to month [ADDRESS_544434] -transplant between the placebo (7 deaths) and rep arixin  (no deaths) groups (p- value = 
0.0111 [Log- Rank]).  
The second phase 2 study [REP0204 ] was conducted in US, Ital y, Spain and [LOCATION_009] and involved 
patients undergoing kidney transplantation at increased risk of developi[INVESTIGATOR_430365]. This was a pi[INVESTIGATOR_430366] -transplant renal dysfunction o n reparixin PK.  Out of 
80 patients randomized, 74 patients (25 reparixin continuous infusion; 23 reparixin intermittent 
infusion; 26 pooled placebo) and 73 patients (24 reparixin continuous infusion; 23 reparixin 
intermittent infusion; 26 pooled placebo) were included in the safety and ITT analysis, respectively.  
The patients were randomized to receive reparixin or placebo as continuous infusion of 2.772 mg/kg/h for 12h rs or 12 intermittent i.v. infusions of 2.244 mg/kg for 30min with 1.5 hour intervals over a total 
period of 22.5h rs or matched placebo.  Overall, the study failed to show a significant difference 
between the treatment groups in the primary efficacy variable (early C Lcr) and in any of the 
secondary efficacy variables assessed up to month [ADDRESS_544435]- transplant.  However, a  trend for a better 
graft function, measured by [CONTACT_37113] (1 -3 and 10- 12hrs after transplant) C Lcr and day 1 to 7 serum Cr 
was observed in the reparixin intermittent infusion group, which however did not reach a statistical signific ance.  Also a higher, even not significant , percentage of patients in this group had immediate 
graft function, with only one patient experiencing graft failure.     
The Medi cal University of Vienna conducted an additional independent placebo- controlled, 
randomized pi[INVESTIGATOR_2268] t r
ial in 32 patients undergoing elective coronary artery by[CONTACT_430416].  
Reparixin was infused at a loading dose of 4.488 mg/kg/h for 30min followed by a maintenance dose 
of 2.772 mg/kg/h for 8h.  The rise in neutrophil count  after CPB was less marked in the reparixin than 
in the placebo group (p < 0.05).  Significant group differences were also detected at [ADDRESS_544436]- CPB.   
Version No. 2 – final 18Jul [ADDRESS_544437] been exposed to reparixin in the clinical studies co mpleted  to date which 
include 103 adult healthy subjects (100 M/3F), 17 patients with different grades of renal impairment 
(12M/5F), 16 patients undergoing cardiopulmonary by [CONTACT_6476] (10M/6F), 46 patients undergoing lung 
transplantation (23M/23F) and 48 patients undergoing kidney transplant (31M/17F).  Exposure 
included short or prolonged i.v. infusion up to 10.6 mg/kg over 30min or 133 mg/kg over 48h. 
Overall, reparixin was safe and well tolerated in both healthy subjects and critically ill patients.   
In phase 1 studies, no deaths, Serious Adverse Events ( SAEs ) or A dverse Event (AE)-rel ated 
withdrawals were reported.  The majority of AEs reported were of mild intensity.  All subjects had 
recovered completely or had ongoing adverse events of mild intensity when they were  discharged.  
The safety of reparixin was confirmed also in patients with different grades of renal impairment.  In the interaction study no safety concerns were raised during co- administration of 
midazolam/tolbutamide with reparixin. 
During phase 2 studies, AE and SAE profile was similar for both placebo and reparixin groups and no 
particular safety co
ncerns were raised.   
In the lung transplant study there were no AE -related withdrawals o r deaths for either placebo or 
reparixin groups.  A total of 28 pati ents experienced SAEs.  Death occurred in 7 patients, all in the 
placebo group.  Death was due to infections in 4 patients leading to sepsis/bacteraemia (3 patients) or 
pneumonia (1 patient).  One patient died due to a cardiovascular accident.  Coronary ar tery disease  or 
unknown origin was the cause of death reported for the other 2 patients for whom minimal information was available.      
In the kidney transplant study there was 1 AE -related withdrawal in 
 the reparixin continuous infusion 
group.  AEs leading to discontinuation of study drug were reported for 3 patients in the reparixin continuous infusion group and for 1 patient in the placebo group.  One patient in the placebo group 
had an AE (septic shock, pneumonia) leading to death.  SAEs were reported i n 21 patients.  Death 
occurred in 2 patients, 1 in the placebo group (septic shock, pneumonia) and 1 in the reparixin 
intermittent infusion group (no information available).   
No SAEs were reported from the CPB study.   
As to Adverse Drug Reactions (ADRs ), infusion site react
 ions, mainly erythema or aseptic 
thrombophlebitis, w ere one of the most common ADRs.  The relatively high frequency was due to a 
cluster of events occurring in cohort [ADDRESS_544438] f
requent (>10%) ADRs observed in the phase 1 and phase 2 studies were: 
Nervous system disorders  (about 27%), including headache, dizziness, hypoaesthesia, somnolence.  
General disorders and administration site conditions  (about 23%), including cannula site re action, 
injection site thrombosis, infusion site oedema and peripheral oedema, fatigue, lethargy.  
Gastrointestinal disorders  (about 1 4%), including nausea, vomiting, abdominal pain, dyspepsia, 
flatulence , gastroesophageal reflux disease. 
Overall, there was no correlation between the incidence of ADRs and the extent of exposure.  
Moreover, the incidence of ADRs was variable among studies regardless of the clinical condition of 
the population exposed to reparixin, i.e. patients under critical care (lung/kidney transplant or CPB patients) did not experience increased frequency of adverse events attributable to reparixin.  
Version No. 2 – final 18Jul [ADDRESS_544439] 
frequent ADRs were erythema, hypotension, nausea, vomiting; great majority of these were mi ld to 
moderate in nature and none required discontinuation if the Investigational Product.  A total of 5 SAEs 
were reported to date in 4 patients.  Two patients (one randomized to the control group, one to the 
reparixin group) experienced intraperitoneal bleeding which w as judged to depend on the islet infusion 
procedure (not -related to the study treatment) in both cases.  One patient who had received reparixin 
during the first islet transplant was hospi[INVESTIGATOR_430367] (due to graft failur e) and 
diarrhea (possibly due to MMF administration).  Nausea, vomiting and severe gastrointestinal bleeding associated with anaemia developed in a female patient early after the beginning of reparixin infusion; 
upon case evaluation, a medical error was ev idenced, i.e. the patient received a dose of reparixn 3 
times as high as that foreseen in the protocol ; infusion of reparixin was immediately discontinued and 
the patient recovered.  About 2 months later, this same patient required hosp italization for diar rhea and 
worsening of kidney function which were due to immunosupressive medica tions (MMF, tacrolimus).   
2.5. DISEASE REVIEW AND STUDY RATIONALE  
Total pancreatectomy is a surgical procedur e to treat end-stage pancreatic diseases, including , but not 
limited to,  chronic pancreatitis.  Despi[INVESTIGATOR_430368], total pancreatectomy is 
associated with long term complications  which are mostly accounted for by [CONTACT_430417].  
While exocrine insufficiency is considered easier to overcome, t he ensuing surgical brittle  diabetes  
presents wit h a high risk of hypoglyc emic u nawareness that is a leading cause of patient death  [Sarr, 
1993; Berney, 2000; Gruessner, 2004; Garcea, 2009 ].   
After total pancreatectomy, the a bsence of endogenous insulin i s c oupled with the lack of other regulatory 
hormones, such as glucagon, resulting in the well known  poor post -operative diabetes control [Farley, 
1995; Linhean, 1988 ].  Segmental pancreatic  or islet auto -transplantation (IAT) has therefore been 
considered since the 1970s as feasible adjunctive procedures to prevent severe post -surgical diabetes  in 
patients undergoing total pancreatectomy for chronic pancreatitis. IAT offers advantages over heterotopic 
pancreas auto- transplantation  as intraportal islet infus ion is a smaller procedure and should be favoured 
whenever the patient has lost pancreatic exocrine function  [Sutherland, 1978; Hogle, 1978; Gruessner, 
2004; Dong, 2011 ].   
Despi[INVESTIGATOR_040] β-cell mass, as estimated by [CONTACT_430418] (IEQ)/kg body weight, is less than for islet 
allografts, long term successful auto -graft function can be achieved in most patients, with a rate of 
insulin independence as high as >80% of recipi[INVESTIGATOR_840] , even if lower figures have been reported, 
according to the total amount of IEQ infused [Sutherland, 20 12; Pollard, 2011; Dong, 2011 ]. 
In addition to end- stage chronic pancreatitis, IAT  post pancreatectomy has been utilized for an 
expanded series of  pancreatic benign diseases including, pancreatic pseudocystis, insulinomas, etc.  More 
recent ly, patients bearing pancreatic cancer were admitted to IAT with no evidence of hepatic 
recurrence of pancreatic disease up to almost one year follow -up, offering some neoplastic patients a 
chance for post- pancreatectomy glycemic control [ Dong, 201 1; Balza no, 2011 ].  
In contrast to allo -transplantation in type [ADDRESS_544440] been found to be the predominant 
cell types infiltrating  the liver in a syngeneic model of islet transplantation in mice.  Also, the intra-
hepatic mRNA for CXCL1/KC, the murine counterpart of human CXCL8, was strongly induced 
immediately after islet infusion.  Consistent with this results, tra nsplan ted CXCR2 knock out mice had 
a significant improvement in islet function [Citro, 2011] .  Thus, CXCL8 might represent a relevant 
therapeutic target to prevent early graft failure after IAT.  
Version No. 2 – final 18Jul [ADDRESS_544441] of 
reparixin in improving graft survival and function.  Protection from the loss and/or deterioration of 
transplanted islets was evident regardless of the immunological mechanisms involved in islet damage, 
suggesting that the ability of reparixin to modulate early inflammatory responses  readily impact graft 
outcome.  Results obtained with reparixin in the experimental model of multiple low doses of 
streptozotocin further emphasize the ability of reparixin to protect β-cells fro m an inflammatory 
damage which appears to impact subsequent graft outcome . 
Thus, the use of reparixin may emerge as a potential useful medication  in the control of non specific 
inflammatory events surrounding the early phases of IAT.   
Preliminary data obt ained in transpl anted patients recruited in the ongoing pi[INVESTIGATOR_430369] [ADDRESS_544442] of this phase 2/[ADDRESS_544443] udy aimed at assessing  the 
efficacy and safety  of reparixin in improving graft outcome in patients undergoing total (or 
completion) pancreatectomy followed by [CONTACT_430419].   
2.5.1. Selection of dose and treatment schedule in the study  
The dose of reparixin proposed for t his trial (2.772 mg/kg body weight/hour) is the same being 
administered in the ongoing clinical trials in islet allo -tranplantation.  It was originally derived from 
the effective reparixin concentrations found both in “i n vitro”  inhibit ion of  CXCL8 -induced 
chemotaxis of human PMN  and in experiments in mouse models of syngeneic and allogeneic 
transplantation .  Such a dose was found safe in previous phase 1 and 2 studies .  Also, p reliminary data 
obtained in the ongoing pi[INVESTIGATOR_430370] -transplantatio n confirm the efficacy and the safety of 
such a dose.   
Consistent with experimental da ta in animals  and preliminary data in the ongoing pi[INVESTIGATOR_430371]-transplantation , the proposed schedule of administration  (continuous infusion for 7 days ) is 
intended to expose the patient to reparixin throughout the time-window of relevant inflammatory  post-
transplant  events after both allo- transplantation  and IAT  [Pollard, 2011 ; Citro, 2011]. 
2.5.2. Alternative treatments  
There are  no specific pharmacologic treatmen ts addressed to the prevent ion of graft failure  after IAT.  
A trial is currently ongoing to test the potential effect of sitagliptin in IAT  ([STUDY_ID_REMOVED]).  Because 
of this, patients not willing to participate in the study may either be offered to participa te in another 
trial of expe rimental treatment or will not be offered any specific alternative treatment.   
All patients, regardless of study participation, will receive the standard of optimal care for the 
transplanted organ
 (procurement, storage, isolatio n, infusion) and the recipi[INVESTIGATOR_841].    
2.5.3. Risk - benefit evaluation  
[IP_ADDRESS]. General risks  
Transplantation of islets is associated with several potential risks.  These are intrinsic to the procedure 
and may result from the intra-hepatic islet infusion as well as testing  involved in the care and 
evaluation of transplanted subjects.  All patients receiving IAT are at risk of complication regardless 
of study participation.  
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 18 of 68 
 
[IP_ADDRESS]. Risk related to the Investigational Product 
Results from preclinical studies support the level of drug exposure planned in this study.  Also, past 
clinical experien
ce with the same dose as planned in this study provides a clear cut evidence of 
reparixin safety.  Very few SAEs were reported with this dose even from clinical trials conducted in 
severe clinical conditions such as patients undergoing lung or kidney transplantation. 
Preliminary data obtained in the ongoing pi[INVESTIGATOR_430370] -transplantati on further support the 
safety of reparixin in this clinical setting.  In patients treated with a [ADDRESS_544444] 
frequent ADRs were erythema, hypotension, nausea, vomiting; great majority of these were mild to 
moderate in nature and none required  discontinuation if the Investigational Product.  A total of 5 SAEs 
were reported to date in 4 patients.  Two patients (one randomized to the control group, one to the reparixin group) experienced intraperitoneal bleeding which was judged to depend on the islet infusion 
procedure (not -related to the study treatment) in both cases.  One patient who had received reparixin 
during the first islet transplant was hospi[INVESTIGATOR_430367] (due to graft failure) and 
diarrhea (possibly due to MMF administration).  Nausea, vomiting and severe gastrointestinal bleeding 
associated with anaemia developed in a female patient early after the beginning of reparixin infusion; 
upon case evaluation, a medical error was evidenced, i.e. the patient received a dose of reparixn 3 
times as high as that foreseen in the protocol; infusion of reparixin was immediately discontinued and 
the patient recovered.  About 2 months later, this same patient required hospi[INVESTIGATOR_430372] (MMF, tacrolimus).   
The very short half life of reparixin (t
1/2 1.0- 1.5hrs) represents an important safety factor as plasma 
levels decline rapi[INVESTIGATOR_430373].  This PK profile, coupled with the me chanism of 
reparixin action (reversible inhibition), makes readily effective appropriate stoppi[INVESTIGATOR_004].   
Administration via a high flow central vein, which was proven to be safe in lung and kidney recipi[INVESTIGATOR_840], 
as well as in pati
ents undergoing islet transplant, is proposed for the study to minimize the risk of 
infusion -site toxicity seen in a cohort of volunteers receiving i.v. infusion via a peripheral vein.   
[IP_ADDRESS]. Central line  
The study drug will be administered as a continuous i.v. infusion over 7 days  with a catheter ins erted 
in a (high flow) central vein.  The risks of a central line are not considered study -related risks since a 
central line is routinely placed in patients undergoing post- pancreatectomy IAT  for their routine 
clinical care.  This required a ccess will be maintained for a period of time that might be  slightly  longer 
than that routinely used.  Nevertheless, central line care as routinely practiced by [CONTACT_430420].  
[IP_ADDRESS]. Blood sampling 
In addition to the routine blood sampling, participation in the study will require an amount of blood 
slight
ly higher  than routine sampling at some time points  (not exceeding 5mL at each time point), to 
allow study specific measurements and centralized assay of C -peptide , HbA1c,  inflammatory 
chemokines/cytokines, miR -375 and PK samples.  
[IP_ADDRESS]. Other study related procedures  
No other procedures specifically associat ed to the study a re required.  Type, t iming and frequency of 
some measurements, e.g. stimulation test b y a Mixed Meal Tolerance Test (MMTT ), might  be guided 
by [CONTACT_760], but such measurements are basically part of standard patient care and would be 
performed regardless of study participation . 
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 19 of 68 
 
[IP_ADDRESS]. Potential benefit  
To the patients : According to preliminary data obtained  in islet allo -transplantation , patients 
receiving reparixin  are likely to  benefit with improved auto- graft function, but this  
is to be confirmed .  Patients assigned to the control arm are expected to obtain no 
additional benefit other than tha t established in IAT recipi[INVESTIGATOR_840] .      
To society : This study may identify a useful medication that will make post- pancreatectomy 
IAT more effective for future recipi[INVESTIGATOR_840].  
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 20 of 68 
 
3. OVERALL STUDY DESIGN AND PLAN DESCRIPTION 
3.1. STUDY DESIGN 
The study will be a phase 2/3, multicenter  (US) , randomized, double-blind, placebo -controlled, 
parallel assignment pi[INVESTIGATOR_799].   
The goal of this study is to reach a  total of  100 adult pa tients who are randomized and receiv e IAT 
after total  or completion pancreatectomy .  Patients will be randomly ( 1:1) assigned to receive either 
reparixin [ continuous i.v. infusion for 7 days (168hrs) ], or matched placebo (control group) ,starting 
approximately 12hrs before islet infusion.  The two groups will be balanced within each centre.   All 
patient s who are randomized and receive the Investigational Product  (either reparixin or placebo) will 
be inlcuded in the ITT analysis.  Patients will be in the ITT analysis whether or not they receive IAT, 
because exclusions cannot be made for events occurring after randomization that could be influenced 
by [CONTACT_430421].  
Recruitment will be competitive among the study sites, until the planned number of patients is 
enrolled.  Competitive recruitment has been chosen to increase the speed of recruitment  and to account 
for any difference in tra nsplant rate among study sites.  Each centre will enrol l patients as rapi[INVESTIGATOR_221527], up to a maximum of 40 patients (as per the randomization list) . A maximum of [ADDRESS_544445]- transplant visits scheduled @ day 75+14 and 365 +14 after the 
transplant . 
3.2. STUDY TIME TABLE  
The planned patients are expected to be recruited in a 12 month period.  A follow -up of 12 months is 
planned for each patient. Overall study timelines are reported below. 
• Projected  starting da te (first -patient-in): December 2013 
• Projected completion of patient accrual (last-patient- in):  March 2015 
• Proj
ected study end date (last -patient -last-visit):  March  [ADDRESS_544446] patient.  
 
  
 
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 22 of 68 
 
• Standard laboratory tests including hematology (hematocrit, hemoglobin, red blood cells, platelets, 
white blood cells, differential white blood cells count), c linical chemistry (sodium, potassium, 
serum creatinine, blood urea nitrogen, total bilirubin, a lanine aminotransferase ( ALT ), aspartate 
aminotransferase (AST ) and coagulation ( International Normalized Ratio (INR), partial 
thromboplastin time  (PTT))  [time frame: pre-transplant  hospi[INVESTIGATOR_430360]- transplant  
hospi[INVESTIGATOR_2345]]. 
• Vital signs, i.e. blood pressure (BP) and heart rate (HR) [time frame: p re-transplant hospi[INVESTIGATOR_430374] -transplant hospi[INVESTIGATOR_2345]].  
• ALT/AST, INR/PTT, fibrin degradation products  (XDP s), C-reactive protein (CRP ) [time frame: 
all daily from day 1 up to day 7 after the transplant ; ALT/AST also on day 75+ 5 after the 
transplant ]. 
• Weight loss from pre- transplant value [time frame: day 75 +14 and 365+ [ADDRESS_544447] ant]. 
• Serum level of albumin and pre- albumin (absolute and change from pre -transplant value) [time 
frame: day 75 +14 and 365+14 after the transplant]. 
• Proportion of patients falling into one of the following levels of steatorrhea severity [time frame: 
day 7 5+14 and 365+14 after the transplant]. 
For the purpose of this protocol, levels of steator rhea severity (evaluated in the  4 weeks prior to day 75 +14 
and 365+ 14), are defined as : 
- No steatorrhea; 
- Steatorrhea few times per week;  
- Steatorrhea daily;  
 - Stool incontinence . 
• Proportion of patients falling into one of the following malnutrition risk levels (poor prognosis, 
significant risk, increased risk, normal) according to pre- albumin level [time frame: day 75 +14 and 
365+ 14 after the transplant].  
For the p urpose of this protocol, malnutrition risk levels are defined as [adapted from  Bernstein, 1995] : 
- Poor prognosis = pre -albumin level <5.0 mg/dL  
- Significant risk = pre -albumin level 5.0 to 10.9 mg/dL  
- Increased risk = pre -albumin level 11.0 to 15.0 mg/dL 
- Normal = pre -albumin level > 15.0 (up to 35.0) mg/dL  
• Cmulative  number of epi[INVESTIGATOR_430362] (documented symptomatic; 
asymptomatic) [time frame: from day 75+14 to day 365+ 14 after the transplant] . 
For the purpose of this protocol, the f ollowing definition applies [ Diabetes Care, 2005 ]: 
- Documented symptomatic hypoglycemia  = An event during which typi[INVESTIGATOR_430375] a measured plasma glucose concentration < 70mg/dL.  
- Asymptomatic hypoglycemia  = An event not accompanied by [CONTACT_11017][INVESTIGATOR_10921], but 
with a measured plasma glucose concentration < 70mg/dL.  
• Cumulative number  of diabetic ketoacidosis- related events [time frame: from day 75+14 to day 
365+ 14 after the transplant] . 
For the purpose of this  protocol, a diabetic ketoacidosis event is defined as the presence of [ Pediatrics, 
2004 ]: 
- hyperglycemia (blood glucose >200 mg/dL);  
- pH <7.3 or HCO3 <15;  
- ketones positive in the serum or urine. 
4.2.4. Exploratory endpoints 
• Time course of inflammatory chemok ines/cytokines as assessed by [CONTACT_430407]8, 
CCL2 (MCP -1), CCL3, CCL4, CXCL10 (IP -10), CXCL9 (MIG), IL -6, IL -10, INF-γ, TNF -α, and 
IL-1β [time frame: pre -infusion hospi[INVESTIGATOR_063] (2 basal samples collected 6 to 24 hrs apart; 
Version No. 2 – final 18Jul [ADDRESS_544448] administration  is 
started ) and 6, 12, 24, 72, 120 and 168hrs after the end of  islet infusion] . 
• Proportion of patients who are randomized but do not receive IAT [time frame: transplant day] . 
• Time course of serum microRNA -375 ( miR-375) [time frame : pre -infusion hospi[INVESTIGATOR_063] 
(sample will be obtained before surgery and before Investigational Product administration  is 
started ) and 6, 12, 24, 72, 120 and 168hrs after the end of islet infusion]. 
4.2.5. Phar macokinetic endpoints  
• Plasma levels of reparixin (total and unbound) and relevant metabolites (DF2243Y and 
ibuprofen) [time frame: post -operative day 1, 3, and 5 (steady state)  in all patients ; just prior to, 
and then at 1, 3, 5, 6, 8,  and [ADDRESS_544449] 20 -24 patients ].  This number of patients should guarantee post -treatment 
sampling in at least 10 -12 patients randomized to reparixin (base on a 1:1 randomization).  These 
patients will be enrolled at 2 of the participating sites.   
 
 
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 24 of 68 
 
5. STUDY POPULATION 
The goal of this study is to reach a total of 100 patients who are randomized and receive IAT after 
total (or completion) pancreatectomy , each being randomised (1:1) to receive either r eparixin or 
placebo.   
Patients will be selected from those eligible for IAT following total or compl etion pancreatectomy .  In 
addition to locally accepted eligibility criteria for the IAT (see below) , each prospective patient will be 
randomiz ed provided t hat (s)he fully meets all of the study -specific  Inclusion Criteria and none of the 
study- specific Exclusion Criteria described in Sections 5.1. and 5.[ADDRESS_544450] fulfil  ALL of the following inclusion 
criteria .  
1. Patients eligible for an IAT follow ing total (or completion) pancreatectomy .   
Eligibility to both total (or completion) pancreatectomy and IAT will be based on local ly 
accepted criteria and guidelines  (see also exclusion below) .  The most restrictive criteria will be 
applied  .   
2. Ages > [ADDRESS_544451] given  written info rmed consent, prior to any study -related procedure not part 
of normal medical care, with the understanding that consent may be withdrawn by [CONTACT_430422].  
5.2. EXCLUSION CRITERIA 
Patients w ho meet any of the following criteria are NOT eligible for participation in the study . 
1. Recipi[INVESTIGATOR_22880] a previous IAT (if completion pancreatectomy). 
2. Patient s undergoing total
 pancre atectomy due to either pancreatic cancer or pancreatic benign 
diseases  other  than chronic pancreatitis, including insulinomas, etc.  
3. Patients with inadequate renal reserve as per calculated creatinine clearance (CLcr ) < 60 mL/min 
according to the Cockcroft- Gault formula (1976 ). 
4. Patient s with hepatic dysfunct ion as defined by [CONTACT_430423]/AST > 3 x upper limit of normal 
(ULN)  or increased total bilirubin above the upper limit at local laboratory ).  Patients with 
Gilbert’s syndrome (elevated unconjugated bilirubin levels in the absence of any evidence of hepatic or biliary trac t disease) are not excluded.  
5. Patient s with a preoperative Inte
 rnational Normalized Ratio (INR) > 1.5 or any known 
coagulopathy. 
6. Hypersensitivity to:  
 a) ibuprofen or to more than one non steroidal anti-inflammatory drug ( NSAID ). 
 b) more than one medic
ation bel ongi ng to the class of sulfonamides, such as sulfamethazine, 
sulfamethoxazole, sulfasalazine, nimesulide or celecoxib ; hypersensitivity to sulphanilamide 
antibiotics alone (e.g. s
ulfamethoxazole) does not qualify for exclusion.  
7. Concurrent sepsis (as per positive blood culture(s) and/or fever associated with other signs of 
systemic sepsis syndrome).  
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 25 of 68 
 
8. Treatment with systemic steroids  in the 2 weeks prior to enrolment  (except for the use of <5mg 
prednisone daily or equivalent dose of hydrocortisone, for physiol ogical replacement only) or 
with an y immune modulators in the 4 weeks prior to enrolment.  
9. Patients with pre-existing diabetes  or evidence of impaired β-cells function , based on pre-
operative fasting blood glucose >115 mg/dL and/or a HbA1c > 6.5% , or requi ring treatment with 
any anti-diabetic medication (e.g. insulin, metformin, etc) within the 2 weeks prior to enrolment.  
10. Use of any investigational agent in the 4 weeks prior t o enrolment , including any anti -
cytokine/chemokine  agent s.  
11. Pregnant or breast -feeding women ; unwillingness to use effective contraceptive measures 
(females and males). (NB: pregnancy should be avoided in patients or partners during the first 
month after completing the treatment with the Investigational Product ; no other specific 
warnin gs are described, considering the treatment course of the Investigational Product, its PK 
profile, and the lack of significant adverse effects on mating performance and fertility in animal 
studies).  
12. Patients with past or current history of alcohol abuse based on clinical history and/or past 
treatme
nt for alcohol addiction. 
13. Patients with evidence of pre- operative porta l hypertension as per clinical history and 
abdominal/liver imaging by [CONTACT_430408]. 
Sites will comply with any additional or more restr ictive exclusio n criteria locally accepted, as per 
centre practice.  
5.3. ASSIGNMENT OF PATIENT NUMBER  
Patient number will be assigned in a sequential manner as a patient  is found to be eligible for entry 
into the study and is randomized .  It will consist of the site number, and the patient number e.g. 0102, 
where first [ADDRESS_544452] 2 digits patient number.  If a patient is dropped from the 
study for any reason, the patient’s number will not be reassigned.   
 
Version No. 2 – final 18Jul [ADDRESS_544453] will be either reparixin [R( -)-4-Isobutyl-alpha-methylphenylacetyl-
methanesulfonamide] or matched placebo . 
6.1. PRESENTATION, STORAGE, PACKAGING AND LAB ELING  
6.1.1. Presentation of  Investigational Products 
Reparixin will be provided as concent rate for solution for i.v. infusion packaged into 250 mL clear 
Glass Vials  with the following composition per single (250 mL) unit: 
Reparixin composition - 33mg/mL 
NAME [CONTACT_430468]-UNIT 
FORMULA  FUNCTION OF 
INGREDIENT  REFERENCE  TO QUALITY   STANDARDS  
Reparixin (DF1681Y)  8.25 g  Drug substance  Manufacturer monograph and specification  
Sodium Dihydrogen 
Phosphate Dihydrate  1.96 g  Buffer  European Pharmacopoeia - c urrent edition  
L-lysine monohydrate  4.78 g  Solubilizer  German P harmacopoeia - current editio n 
Sodium hydroxide  qs to pH 8.0  Buffer  European Pharmacopoeia - c urrent edition  
Water for injections  qs to 250 mL  Solvent  European Pharmacopoeia - c urrent edition  
 
Placebo will be physiologic sal t solution ( 0.9% w/v sodium chloride solution) provided as 
commercially available [ADDRESS_544454] 
Reparixin will be manufactured by [CONTACT_49860] (Italy).  Both Investigational products will be packaged 
and labelled by [CONTACT_430424] .   
Reparixin and placebo vials will be supplied along with sterile empty Infusion Bags and corresponding 
Infusion Bag labels
.   
All the materials will have trial- specific labels.  Detail s of packaging and labelling are reported in 
Appendix 14.[ADDRESS_544455] 
An appropriate number of packages will be initially sent to the site as soon as all essential documents 
and FDA/ethics approvals have been obtained.  Additional supplies (reparixin, placebo, Infusion Bags) 
will be sent on demand, according to enrolment rate.  
The Investigational Product must be kept at a temperature not exceed ing 30°C and must not be frozen.  
A temperature probe will accompany the drug on shipment.  Temperature range reached during 
shipment will be 
verified on receipt, so that potential stability concerns during shipment can be 
investigated and appropriate action taken.  
Version No. 2 – final 18Jul [ADDRESS_544456] (or designee) will check the package for accurate delivery 
and acknowledge receipt; any deviations from expected package content (inconsistency, damages) 
should be immediately reported to Dompé (or designee) and the use of the drug suspended until 
authorization for its continued use has been given by [CONTACT_58231]é (or designee).   
The Investigational Product must be stored in a secure location, in a temperature controlled room.  
Temperature recor
ds must be availab le for the Unblinded- CRA ( U-CRA ) to review at monitoring 
visits; any deviations from the recommended storage conditions should be immediately reported to Dompé (or designee) and the use of the drug suspended until authorization for its continued use has 
been given by [CONTACT_58231]é (or designee). 
The Investigational Product will be dispensed only by [CONTACT_121936] (or designee).  The Investigator 
will ensure that 
study treatment is only administered by [CONTACT_430425].  
Pharmacists will be provided  with the ‘Instru ctions to the Pharmacy’, a booklet detailing instructions 
for Investigational Product handling and preparation of the dosing solution.   
6.1.4. Preparation of the Dosing Solution 
The dosing solution for infusion will be prepared at the designated Pharmacy or authorized location 
within each centre according to local guidelines for sterile re-consitution of i.v. injectable solutions. 
For each 750 mL dosing solution volume, the content of a Vial (250 mL) will be diluted with 500 mL 
of 0.9% sterile s
aline to dispense reparixin as 11.00 mg/mL solution.  The dosing solution will be 
placed in a 1000 mL sterile empty Infusion Bag.  Dosing solutions will be prepared and used within  72 
hours from preparation, unless the site has more restrictive rules.  
A double- tear off label will be attached to each prepared bag, reporting patient number and relevant 
blinded information.  Infusion Bags for the same patient/administration course will be numbered in a sequential manner, starting from No. 1.  Labels for the Investigation product administration during the 
[ADDRESS_544457] (or designee) will make the Infusion Bags available to the hospi[INVESTIGATOR_430376].  
6.1.5. Blinding  
Reparixin solution in the vial (33mg /mL) has a slightly different appearance (pale yellow colour) as 
compared with placebo.  Also, a transient foamy layer occasionally results from the preparation of the reparixin dosing solution.  However, once the foamy layer, if any, had subsided, the dosing solution of 
reparixin in the Infusion Bag will be indistinguishable from that of placebo.  
Individual treatment codes will be provided in tamper -resistant  system 
 (either sealed envelopes or 
scretch cards)  to the Pharmacist (or designee).  They must be kept in a secure location accessible only 
to designated staff in order to prevent dissemination of the treatment to personnel involved in study 
conduct who must remain blind.  
The Pharmacist (or designee) will break the treatment code only after the patien t-specific “IP 
Prepa
ration Order Form” is received from the Investigator.  The individual  code matching the patient 
randomization number will be opened to prepare the dosing solution matching the patient 
randomization number.       
The Investigators can re quest to an indepe ndent facility (either by [CONTACT_430426]) an 
individual code  in the event of an emergency only, where knowledge of the blinded treatment for that 
patient  could influence further patient care.  Any potential unauthorized code break and the reason 
Version No. 2 – final 18Jul [ADDRESS_544458] 
ADMINISTRATION 
Patients will receive either reparixin at a dose of 2.772 mg/kg body weight/hour for 7 days (168 hrs) or 
matched (flow rate/length of in fusion) placebo, according to the randomization number.   
The dosing solution (if reparixin, 11mg/mL) will be administered as a continuous i.v. infusion into a 
(high flow) centra
l vein, by [CONTACT_430427] (see below), 
as per treatment schedule.  
Infusion of the Investigational Product will start approximately 12hrs (allowed range 6 -18hrs) before 
the a
nticipated time when islet infusion is started.  The Investigator will identify the time to start study 
drug administration.  
The pump rate will be adjusted to provide an infusion rate of approximately 0.25mL/kg/hour.  Actual 
infusion rate (
mL/hour), adjusted to body weight, is tabulated in Appendix 14.3.  Figures in the 
appendix represent mathematical rounding of original infusion rates derived from the following 
formula: 
Infusion rate (mL/hour)    =  dose (mg/kg/hour) x body weight (kg) 
11.00 mg/mL 
Such a rounding affects actual administered dose/kg/hour by [CONTACT_21316] 1%. 
6.3. CRITERIA FOR SCHEDULE ADJUSTMENT/DOSE -MODIF ICATION/ 
DISCONTINUATION OF INVESTIGATIONAL PRODUCT  
6.3.1. Criteria for schedule adjustment or dose modification  
No schedule adjustment and/or dose modification is foreseen, except for discontinuation of drug as detailed below. 
6.3.2. Criteria for discontinuation of Inv estigational Prod uct 
Phase [ADDRESS_544459] on plasma concentrations of a major, marginally active metabolite, carboxy -reparixin 
(DF2243Y), which was found to accumulate  over time along with the increased elimination half -life.  
Even if toxicological results to date suggest that DF2243Y does not raise any safety concern, limited 
experience in humans recommends discontinuation of  the drug in case of renal impairment as it would 
not be possible to predict the risk associated with elevated plasma levels.   
Because reparixin undergoes extensive hepatic metabolism, hepatic dysfunction should also be 
monitored to 
avoid an increase in plasma levels.  An asymptomatic, self -limited  transaminitis is 
consistently seen after islet transplantation into the liver.  This is characterized by [CONTACT_430428]/ALT which peaks at about [ADDRESS_544460] reparixin metabolism.  [ Rafael, 2003; Barshes, 2005].  
Therefore, the Investigational Product should be immediately discontinued  in case the patient 
develops renal  or hepatic dysfunction defined as:  
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 29 of 68 
 
Renal dysfunction : the occurrence of both CLcr < 60 mL/min and urine output < 0.5 mL/kg/hour 
on two consecutive samplings.  Transient alterations of serum creatinine or 
urine output, other than defined above, do not indi cate a renal dysfunction 
that would cause impaired excretion of DF2243Y.   
Hepatic dysfunction : the occurrence of ALT/AST > [ADDRESS_544461] and total bilirubin > 3mg/dL [> 51.3 
µmol/L].   
Renal and hepatic function will be evaluated daily from post- operative day [ADDRESS_544462] will be immediately discontinued  in the  case the patient withdraw 
his/her consent or has not  received the transplant .  
Patients who discontinue the treatment with the Investigational Product will not be withdrawn from 
the study by [CONTACT_15094], but will complete observations as per the protocol, unl ess otherwise they 
withdraw  their consent . 
If the Investigational Product therapy is prematurely discontinued the primary reason for 
discontinuation must be recorded in the CRF.   
6.4. ACCOUNTABILITY 
All supplies will be maintained under adequate security by [CONTACT_430429].   The Investigator will ensure that study treatment is only administered by [CONTACT_430430]-
investigators on the FDA form [ADDRESS_544463] (or designee), (s)he will check f
 or 
accurate delivery and acknowledge receipt by [CONTACT_430431]é (or designee) and returning it to Dompé (or designee) .  A copy will be retained for the 
Investigator/Pharmacy file.  
The dispensing of the Investigational Product will be carefully recorded on appropriate drug 
accountability
 forms provided by [CONTACT_58231]é (or designee) and an accurate accounting will be available 
for verification by [CONTACT_1629]  U-CRA at each monitoring visit.  
Drug accoun tability records  will include:  
• confirmation of receipt of the Investigational Product at the trial site,  
• the inventory at the site ( vials),  
• details
 of each bag preparation , 
• the use by [CONTACT_6904],  
• disposition of unused vial (s), 
• account of 
any Investigati onal Product acc identally or deliberately destroyed. 
Version No. 2 – final 18Jul [ADDRESS_544464] and/or patients.   
Records should be maintained to adequ ately document t hat: 
• the patients were provided the doses specified by [CONTACT_760]/amendment(s),  
• all Investigational Product provided was fully reconciled. 
The U- CRA will 
review the drug accountability forms for consistency with drug administraiton (as pe r 
CRF) and remai
ning unused Investigational Product vials.  
Investigational Product which has been dispensed to a patient and returned unused will not be 
re-dispensed to a diff
erent patient.  
Unused Investigational Product must not be discarded or used for any purpose other than the present study.  Any rema
ining test material at the end of the trial will be returned to Dompé (or designee) or 
disposed of, as determined by [CONTACT_58231]é (or designee). 
6.4.1. Assessment of compliance  
Compliance will be assured by [CONTACT_108443](s) within the centre in charge of Investigational Product administration.   
Immediately before the use of an Infusion Bag is started, the removable label on the bag will be 
detached and attach
ed to the relevant page of the CRF.  Actual date and time of infu sion start and end 
for each container will be recorded in the CRF, as well as the infusion rate(s).  Temporary interruption 
of > 30 min duration (cumulative within each 24 hours) during drug administration should also be 
reported. 
Compliance with the study  product dosing sche dule will be verified by a CRA during on- site 
monitoring visits, as per records in the CRF, versus accountability records.  
6.5. CONCOMITANT THERAPY  
Any medications  required for the patient's welfare are permitted and will be given at the discretion of 
the Investigator, except for drugs described in paragraphs below.  
Administration of all prior (4 weeks pr ior to enrolment) and concomitant medications  (CMEDs ), apart 
from the agents listed below, during hospi[INVESTIGATOR_430377] .  Only medications used for  SAE, oral hypoglycemic drugs as well as medications that should not 
be used (see Section 6.5.1 below) will be reported  after hospi[INVESTIGATOR_2345].   
All the details as per the CRF fields (sequential num ber, drug name, indicat ion, starting dose, 
start/stop  date , route of administration ) will be recorded .  Change in dose will not be tracked.  
The following agents do not need to be recorded: 
 Saline and other hydration solutions (including additional electrolytes)  
 T otal parenteral nu trition  and ent eral feeds  
 Homeopatic medications 
 Elective vitamins and minerals  
 Topic al agents with no or negligible systemic absorption  
 Osmotic laxatives and locally acting antacids  
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 31 of 68 
 
6.5.1. Other treatments  
Drugs required during surgery will be administered as per centre practice.  
The following prophylactic anticoagulation  is suggested to be used in patients enrolled in this study  
- Heparin will be administered at a dose of 70 U/kg, divided equally between the islet bags, followed 
by 3 U/kg/hour infused i.v. for the next [ADDRESS_544465]-transplant.    
Prophylactic antico agulation manag ement (choice of medication and/or doses) might be adjusted on 
the basis of clinical requirements (e.g. occurrence of bleeding) and/or centre practice.  Low Molecular 
Weight Sulfate Dextran cannot be used in this trial.   
Glycemic control in the early post- transplant period  w ill be achieved by [CONTACT_430432] 80-180mg/dL. Patients wil l be tested for blood sugar by [CONTACT_171254] a 
minimum of 4 times per day. Insulin will be titrated to maintain fasting and pre -meal blood sugars in 
the range 80- 125 mg/dL, and [ADDRESS_544466] -prandial glucoses <180 mg/dL. For patients on continuous 
enteral or p arental feeds, insulin will be titrated to maintain glucose in the range 80- 140 mg/dL . 
 
The following medications should not be used  in this study:  
- Systemic steroids ( i.e. intravenous, intramuscular, oral; intra-articular injection allowed ): from 2 
weeks prior to enrolment up to the end of the study ; use of <5mg prednisone daily or equivalent 
dose of hydrocortisone, for physiological replacement only is allowed. 
- Any investigational agents : from 4 weeks prior to enrolment up to the end of the study; 
- Any anti-cytokine/chemo kine medications (e.g. anti -TNFα): from 4 weeks prior to enrolment up to 
the end of the study; 
- Any i mmune modulators: from 4 weeks prior to enrolment up to the end of the study; 
- Low Molecular
 Weight Sulfate Dextran;  
- Oral hypoglyc em
ic agents and an y drugs that influence insulin sen sitivity.  
 
Since exposure to ibuprofen after administration of reparixin 2.77 2 mg/kg/h for 48hrs is in the range 
of that obtained after a standard therapeutic single dose of ibuprofen (300mg), concomitant 
administration of NSAIDs, including cyclo -oxygenase- [ADDRESS_544467] , as this may increase the risk of cyclo -
oxygenase- dependent adverse affects . 
 
Version No. 2 – final 18Jul [ADDRESS_544468] of acceptable assessment/procedure time windows is detailed in Appendix 
14.5.  Methodological details are reported in Appendix 14.[ADDRESS_544469] criteria for total (or completion) pancreatectomy followed by [CONTACT_430419].  
Consented patients will undergo the following scre ening evaluation, within 72 hours prior to 
randomization.  
BP, HR, body weight (kg) and height (m) will be measured. 
A baseline blood sample will be taken prior to any intervention  for safety laborator y tests (assay as per 
centre practice ).  These include hematocrit, hemoglobin, red blood cells, platelets, white blood cells, 
differential white blood cells count, sodium, potassium, serum creatinine, blood urea nitrogen, total 
bilirubin, ALT, AST, INR , PTT .  Albumin and p re-albumin will be also measured.   
Pregnancy test (urine dipstick or blood test) will be performed, if appropriate. 
Renal reserve will be assessed 
by [CONTACT_430433] ( Cockcroft -Gault; 1976 ; see details in A ppendix 14.6. 2).  
Hepatic function will be assessed by [CONTACT_42386]/AST and bilirubin. 
Concurrent sepsis wil l be diagnosed by [CONTACT_430434] e(s) and/or fever associated with other signs of 
systemic sepsis syndrome.  
Pre-operative portal hypertension will be diagnosed as per clinical history and abdominal/liver 
imag
ing (e.g. presence/absence of varices, splenomegal y, Doppler waveforms and flow direction) by 
[CONTACT_430408] (e.g. duplex ultrasonography, spectral Doppler imaging and Color Doppler 
imaging, power Doppler imaging). 
Two basal  serum samples collected 6 to 24 hrs apart  will be stored for centralized assay of pre-
transplant chemokines/cytokines; similarly, a basal sample will be store d for centralized assay of  pre-
transplant  miR-375 (see Appendix  14.6.3) .  All basal  samples will be obtained before surgery and 
before Investigational Product administratio n is started.  
Compliance with inclusion/exclusion criteria will be verified vs demographic, laboratory test results 
and clinical history/ infor
mation available as per local standard clinical practice.   
Eligible patients will be  randomized (randomizati on number assigned) by [CONTACT_39595] (or designee) 
before starting the infusion of the Investigational Product. 
A screening form will be completed for all patients who signed the Patient Informed Consent 
Document, regardless of 
subsequent entry into the study .  Patients will be identified by [CONTACT_430435]; patient number if enrolled or reasons for exclusion from the study will be recorded. 
7.1.2. Start of infusion with the Investigational Product 
Infusion of the Investigational Product will start approximately 12hrs ( 6-18hrs ) before the anticipated 
time of islet infusion.  The Investigator will identify the time to start study drug infusion.   Infusion may 
be halted during pancreatic surgery if required , provided that interruption is not longer than 6 hours.   
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 33 of 68 
 
The infusion pump will be set to provide the infusion rate corresponding to the planned dose.  Infusion 
rate (mL/hour) corresponding to each unit increment (kg) of body weight, is reported in Appendix 14.3 .  
Immediately before the start of infusion, the removable label on the Infusion Bag No. 1 will be detached 
and attached to the rel
evant page of the CRF.  Starting time of drug administration and infusion rate will 
be recorded in the CRF. 
7.1.3. Islet isolation and transplantation 
Techniques for pancreas removal  will be used, as per centre practice, including requirement for 
concomitant splenectomy .   
Islet preparation : Site will process islets by [CONTACT_430436].  The pancreas w ill be distended by 
[CONTACT_430437] /neutral protease ; if duct disruption pr ohibits 
intraductal infus
ion, enzyme will be manually injected into the pancreatic 
parenchyme.   Pancreatic digestion will be performed using the semi -automated 
method of Ric
ordi.  Purification will be performed when necessary to reduce tissue 
volume, dependent on site specific standards for islet manufacturing, using density 
centrifugation with COBE 2991.  Samples will be taken from the pancreatic preservation so lution and final islet product for sterility testing by [CONTACT_430438].   
 Islet mass will be assessed
  by [CONTACT_430439] 14.6.1 and 
quanti
fied as total 
IEQ and IEQ/kg body weight.  The final product is suspended in a 
[ADDRESS_544470] is supplied in one to three 200 mL infusion bags, containing a 
minimum dose of >10,000 IEQ total. 
Islet infusion:  At all sites, islets will be transplanted on the same day as the total pancreatectomy 
procedure . 
 The islet mixture will be  delivered slow ly by [CONTACT_430440] 
a tributary of the portal vein.  Access to the portal vein may be obtained by [CONTACT_430441], 
ultrasonographic, or real -time CT guidance.   
 At minimum, p ortal v enous pressure will be monitored (direct venous measurement) 
before initiation, 
mid-way, and after completion of islet infusion. In case the portal 
pressure re aches >35 cmH 2O, islet infusion will be put on hold, and restart ed when 
portal pressure has dropped.  In the rare event that portal pressure does not lower 
(within a 30 min interval), infusion is definitely stopped and any remaining tissue 
either discarded  or placed in another tissue (e.g. peritoneal cavity, duodenal wall, 
underneath the kidney capsule , etc. ). 
The following isolation and operati ve details will be recorded in the CRF, as per documentations 
provided by [CONTACT_430442] :  
• Date and time of isolation (procedure completed).  
• Date and time of infusion (start and end of infusion) ; 
• IEQ/kg infuse d.  Islet 
will be count ed as detailed in  Appendix 14.6.1; 
• Total islet infusion volume ; 
• Pre-, mid -way,  and post- infus
ion por tal pressure. 
Version No. 2 – final 18Jul [ADDRESS_544471] will continue during hospi[INVESTIGATOR_4408].  
Infusion Bag s will be used in a sequential m anner (No. 1, No. 2, No. 3 etc.) and infusion of the 
Investigation al Product will progress non-stop up to a total of 7 day (168h rs) administration.   
The removable label on each new Infusion Bag  will be detached and attach ed to the relevant page of 
the CRF.  Start date/time and stop date/time for each Bag will be recorded in the CRF, along with 
accidental interruptions of study drug infusion for > 30min  (cumulative within each 24 hours). 
7.1.5. Post-operative a ssessment s 
The following will be assessed during hospi[INVESTIGATOR_430378].  Measurement will be 
performed a s per cent re practice, unless otherwise specif ied.   
• Renal function (CLcr, urine output) :  Renal function will be assessed daily from post -operative day [ADDRESS_544472] of care.  Urine 
volume will be measured at urination (measuring cylinder); corresponding collection time will be 
calculated from the previous urination.  Depending from  feasibility and patient compliance, ideally  
more than one measurement should be done over a 24- hour period to get the best estimate of urine 
output.  
• Total bilirubin :  Total bilirubin will be assessed daily from post -operative day 1 up to the end of 
study drug infusion as part of hepatic function evaluation.   
• XDP, ALT/AST, INR/PTT, C -reactive protein (C RP):  These will be measured daily from day [ADDRESS_544473]- transplant.   
• Chemokines/cytokines [CXCL8, CCL2 (MCP -1), CCL3, CCL4, CXCL10 (IP -10), CXCL9 (M IG), 
IL-6, IL -10, INF-γ, TNF -α, and IL-1β ]: A blood sample will be obtained @ 6, 12, 24, 72, 120 and 
168hrs after the end of  islet infusion.  Samples will be handled and stored for the centralized assay, 
as detailed in Appendix 14.6.3. 
• miR-375: A blood sample will be obtained @ 6, 12, 24, 72, 120 and 168hrs after the end of  islet 
infusion.  Samples will be handled and stored for the centralized assay, as detailed in Appendix 
14.6.3. 
• Pharmacokinetics [plasma levels of reparixin (total and unbound ) and relevant metabolites 
(DF2243Y and ibuprofen) ]: A blood sample will be obtained in all patients randomized and treated 
with the Investigational product on post -operative day 1, [ADDRESS_544474] administration.  
Samples will be handled and stored for centralized assay, as detailed in  Appendix 14.6.3.    
• Safety labor atory tests : Laboratory tests will be performed  before hospi[INVESTIGATOR_2345]. 
• Vital signs , i.e. blood pressure ( BP) and heart rate (HR) will be measured before hospi[INVESTIGATOR_2345].  
During hospi[INVESTIGATOR_4408], all AEs (see details in Sections 8.2.) and CMEDs (see details in Sections 6.5.) 
will be recorded.   
For all measurements above, the actual date and time of assessment , including date of sampling,  wil l 
be recorded in the CRF.  
Version No. 2 – final 18Jul [ADDRESS_544475] -transplant, hospi[INVESTIGATOR_430379] (the major surgical procedure in total 
pancreatectomy followed by [CONTACT_430419]) and will comply with each site’s hospi[INVESTIGATOR_137288].  However, at all sites, at least the following criteria will be complied with: “ A patient will be discharged if he/she at 
least is ambulating, has adequate nutrition (oral, enteral, or T otal Parenteral Nutrition (TPN ), is not 
requiring any intravenous medications which require inpatient monitoring, pain is adeq uately treated, 
and he/she has a stable plan for glycemic control (management of blood glucose testing and insulin 
administration at home) ”.
 
7.2. FOLLOW -UP PROCEDURES AND ASSESSM ENTS  
Since hospi[INVESTIGATOR_2345], patients will self monitor  glucose levels and insulin intake according to 
standard clinical instructions at the site.   Insulin will be administered to target fasting and pre- m eal 
glucose levels in the range 80-125 mg/dL, and [ADDRESS_544476] -prandial glucoses <180 mg/dL. For patients 
on continuous enteral or parental feeds, insulin will be titrated to maintain glucose in the range 80-140 
mg/dL .   
The Investigator will identify if- and the date when - it is appropriate for the patient to stop insulin 
intake, according to standard of centre practice.  Regardless the patient is on or off insulin , he/she will 
report on a Diary  Card (see Appendix 14 .7) his/her self monitored glucose levels for 14 consecutive 
days prior to the follow -up visits on day 75+14 and 365+14 after the transplant: glucose levels will be 
measured at least t wo times a day : 1) after an overnight fast  (or anyway before breakfast if the patient 
is still on a tube feed and TPN) ; 2) within [ADDRESS_544477] their  daily  insulin intake.  
Patients will attend the cent re for study assessment s on 2 follow -up visits scheduled on day 75+14 and 
365+ 14 after the transplant.   
At each visit, the following will be evaluated/measured  in all patients as per cent re practice, unless 
otherwise specified.   Measurements, including the actual date and time of assessment, or the date of 
sampling, will be recorded in the CRF.  
• Patient weight.  
• Retrospective self-measured glucose and ins ulin requirement  data in the 2 weeks prior to the visit 
will be reviewed and  average (previous week) insulin requirement at each time point as well as 
insulin -independence / insulin -dependence status will be assessed.  
• Retrospective epi[INVESTIGATOR_430380].  Events of d oc
umented  hypoglycemia in the interval  will be obtained from review of the 
patient’s home glucometer download from between visits and/or patient glucose logs.   
• Retrospective severity of steatorrhea in the 4 weeks prior to the visit will be evaluated.  
• A blood sample will be taken prior to the meal administration to measure HbA1c, albumin and pre -
albumin.  ALT/AST will be also measured  on day 75+5.   
• A MMTT test will be performed as detailed in Appendix 14.6.4.  Blood samples will be drawn @ 0 
(2 basal samp les in the range between -20 to 0 prior to the meal ) and  15, 30, 60, 90, 120, 180, 240  
min after the meal for glucose, C-peptide and insulin  measurement.  
• β-score will be calculated according to  Ryan (2005)  (see Appendix 14.6. 5 fo r details).  
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 36 of 68 
 
C-peptide and HbA1c will be measured by a centralized laboratory  with CLIA  certification and 
National Glycohemoglobin Standardization Program ( NGSP ) certified assay .  De tails of h andling and 
storage of samples as well as data handling are reported in Appendix 14.6.3. 
Any SAEs that occurred after hospi[INVESTIGATOR_430381], as well as CMEDs, as 
appropriate.  
Patients should be strongly motivated to attend the centre for the planned follow -up visits.  Howeve r, if 
a patient cannot refer to the site for protocol assessments, the Investigator will try to obtain any relevant 
information  from the patients, including documents /lab results available from loca l medical care.   
7.3. EARLY PATIENT WITHDRAWAL  
7.3.1. Criteria for withdrawal from the study  
Patients will be informed that they have the right at any time to withdraw from further participation in 
the study ( withdrawal of consent ), without prejudice to their medical care, and without being obliged 
to state their reasons.  However, during the consent process, patients will be also educated about the 
scientific relevance of their continued participation as well as the deleterious effect that missing data 
will have on tr ial integrity.   
If a patient fails to return to the centre for a scheduled visit, all reasonable attempts should be made to 
contact [CONTACT_430443] a SAE.  Likewise if a patient 
declares his/her wish to discon tinue from the study e.g. for personal reasons, an attempt should be 
made to establish that the true reason is not a SAE (bearing in mind the patient is not obliged to state 
his/her  reasons).  The term withdrawal of consent should be used only when the pat ient no longer 
wishes to participate in the trial and no longer authorizes the Investigators to make efforts to continue 
to obtain his/her outcome data. Ideally, if patients withdraw their consent, it should be done in writing. 
Patients who have discontinued the study treatment should be a nyway followed to ensure that primary 
and secondary outcome measures are assessed, unless they formally have withdrawn consent.  
It is important that any randomized patient remains in the study and is followed for both effi cacy and 
safety outco
mes, regardless he/she has completed or discontinued the study treatment.  Investigators 
will be trained about the importance of patient retention and full data capture.  Also, all reasonable 
attempts should be made by [CONTACT_737] s to emphasize continued patient’s participation for the 
full duration of the trial.     
Any withdrawals must be fully documented in the CRF. 
7.3.2. Replacement policy  
No patient who has been randomized and withdraws from the study for any reason will be replaced.  
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 37 of 68 
 
8. ADVERSE EVENTS  
8.1. DEFINITIONS  
8.1.1. Definition of an Adverse Event  
An adverse event (AE ) is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a medicinal product and which does not necessarily have a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the use of 
a medicinal product, whether or not related to the medicinal product [Clinical safety data 
management: Definitions and Standards for Expedited Reporting] .  
8.1.2. Definition of a Serious Adverse Event  
A Serious Adverse Event  (SAE ) is defined as any untoward medical occurrence that at any dose:  
• results in death,  
• is life -threatening (i.e. the patient was at risk of death at the time of the event.  It does not refer to 
an event which hypothetically might have caused death if it were more severe),  
• requires inpatient hospi[INVESTIGATOR_1081], 
• results in persistent or significant disability/incapacity,  
• is a congenital anomaly/birth defect,  
• is an important medical event that based upon appropriate medical judgment, may jeopardize the 
patient and may requi
re medical or surgical intervention to prevent one of the outcomes listed 
above. 
All AEs should be followed- up to determine the outcome  of the reaction.  The Investigator should 
follow up the event until resolution or stabilization of the condition.  It is the Investigator's 
responsibility to assure that the subjects experiencing an AE receive definite treatment for any AE, if 
required. 
8.2. EMERGENCY PROCEDURES  
The treatment allocation for each patient will be provided in individual tamper -resistant  decoding 
systems (sealed envelopes or scratch cards)  to the Dompé Pharmacovigilance department .   
The Investigator can request treatme nt allocation for a patient to an independent facility (either by 
[CONTACT_430426])  in case of emergency where knowledge of the double- blind treatment 
may influence the further care of the patient.   
If a code is opened for any reason, the reason behind it will be recorded  . 
8.3. RECORDING  
AE data should be obtained through observation of the patient, from any information volunteered by 
[CONTACT_102], or through patient questioning.  Specifically, patients will be asked about any epi[INVESTIGATOR_430382]- related events occurring from the transplant day up to day 
75+[ADDRESS_544478] -transplant.  Any epi[INVESTIGATOR_430383], as appro priate.   In addition, 
the Investigator will capture and report epi[INVESTIGATOR_113018] -documented hypoglycemia throughout study 
participation.   
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 38 of 68 
 
All AEs (serious and non -serious) encountered during the clinical study will be re corde d in the 
appropriate section of the CRF  as per the recording period defined in paragraph 8.3.1.  It is important 
that this includes the duration of the AE (onset/resolution dates), the relationship to the drug, the 
severity, the outcome and relevant  concomitant treatments dispensed (or other ac tion taken) (see 
Sections 8.3.2. and 8.3.3 . below).   
8.3.1. AE r ecording  period  
All AEs (serious and non- serious) which occur during each hospi[INVESTIGATOR_430384].   
In addition, SAEs and relevant untoward event s that occur  subsequent to each hospi[INVESTIGATOR_430385]. 
8.3.2. Relationship of AEs to the Investigational Product 
The Investigator will assess the possible relationship between the AE and the investigational medication, according to the criteria in  the Table  below:  
Relation ship of the Adverse Event to the Investigational Product  
None (Intercurrent 
E
vent)  An event that is not and cannot be related to the Investigational Product, 
e.g. a surgical intervention for nevus removal performed during the study, 
but planned before pati ent enrolment into the study  
Unlikely (remote)  Relationship is not likely e.g. a clinical event including laboratory test 
abnormality with temporal relationship to drug administration which makes 
a causal relationship improbable and in which other drugs, chemicals or 
underlying disease provide more plausible explanations 
Possible Relationship may exist, but could have been produced by [CONTACT_102]’s 
condition or treatment or other cause 
Probable Relationship is likely, the AE abates upon discontinuation of Investigational 
Product and cannot be due t
o the patient’s condition 
Highly Probable Strong relationship, the event abates upon discontinuation of Investigational Product and, if applicab
le, re-appears upon repeat exposure 
An Adverse Drug Reaction (ADR)  is defined as an adverse experience which is a reasonably likely 
to have been caused by [CONTACT_33641].  Any AE reported in the study having a possible, probable or highly 
probable relationship to study drug will be considered as an ADR. 
8.3.3. Severity of AEs  
The In vestigator will grade the severity of any AE using the definitions in  the Table  below . For each 
epi[INVESTIGATOR_1865], the highest severity grade attained should be reported.  
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 39 of 68 
 
Severity of the Adverse Event  
Mild  Grade 1 - Does not i nterfere with patient’ s usual function ( awareness of 
symptoms or signs, but easily tolerated [acceptable]).  
Moderate Grade 2 - Interfe res to some extent with patient’ s usual function (enough 
discomfort to interfere with usual activity [disturbing]).  
Severe  Grade 3 - Interf eres significantly with patient’ s usual function (incapacity to 
work or to do usual activities [unacceptable])  
 
8.4. SERIOUS ADVERSE E VENT REPORTING  
8.4.1. Reporting Procedure for Investigators to  Dompé  (or desig nee) 
The Investigator must report all SAEs, regardless of presumed causal relationship, to Dompé (or 
designee) by [CONTACT_3719] e -mail within [ADDRESS_544479] details for SAE reporting 
are provided in the section “Contact [CONTACT_7171]”.     
Information on SAEs will be recorded on a specific Non- Carbon Repeat SAE  f orm.  Both electronic 
and blank paper copi[INVESTIGATOR_430386]’s Site File.  Follow -up reports (as many as 
required) should be completed and faxed /e-mailed  following the same procedure above.   
Whenever more than one SAE is observed, t he Investigat or should identify which is the primary 
adverse event, i.e. the most relevant one.  If other events are listed in the same report, the Investigator, 
along with their relatedness to the Investigational Product, should identify which adverse eve nts are 
serious and which are non- serious.   In any case, the I nvestigator is requested to record his/her opi[INVESTIGATOR_243886](s) with the investigational medication. 
8.4.2. Reporting Procedure for Investigators to IRB  
In addition t o reporting the SAE to Dompé, the Investigator must also comply with the requirements 
related to the reporting of SAEs to the IRB which approved the study. 
The requirements of IRB varies from one state and indeed one IRB to another ; however , as a 
minimum r equirement, the Investigators must promptly report all serious unexpected* ADRs, life-
threatening problems or deaths to their IRB. Dompé (or designee)  will inform I
 nvestigators  of all serious unexpected ADRs  which are reported to 
Dompé from other Investigators.  These SAEs should also be reported promptly to the IRB in 
compliance with the local regulations.   
Copi[INVESTIGATOR_317839]’s 
Files.  
* For the purpose of this study, all ADRs are assumed to be unexpected .   
8.4.3. Reporting Procedures to the FDA  
During the course of the clinical trial, Dompé (or designee) shall inform the FDA of any serious unexpected ADR* as soon as possible and in no event later than:  
(a) seven  calen dar days af
 ter becoming aware of the information if the event is fatal or life 
threatening ; and 
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 40 of 68 
 
(b) fifteen  calendar days after becoming aware of the information if the event is neither fatal nor life 
threatening. 
Dompé (or designee) shall, within 8 days a fter having informed the FDA under paragraph ( a), submit 
a complete report in respect of that information that includes an assessment of the importance and 
implication of any findings made.   
Furthermore, Dompé (or designee) shall follow up safety informat ion and shall report final findings in 
a written safety report as soon as the relevant information is available.  
If the results of an investigation show that an adverse drug reaction not initially determined to be 
reportable is recl
assified as reportable, Dompé (or designee) shall report such reaction in a written 
safety report as soon as possible, but in no event later than 7/15 calendar days after the determination 
is made.  
Dompé (or designee) will inform the FDA of all serious ADRs which are reported from other 
Investigators.   
8.5. ADVERSE EVENT EXEMPTION  
The following events will neither require recording nor reporting, as they are considered routinely 
associa ted to the pancreatectomy or to the transplant procedures: 
- Delayed Gastric Emptying requiring insert ion of a centr al line for Total Parenteral Nutrition or 
insertion of a nasojejunal tube for Enteral Nutrition; 
- Increased ALT/AST levels up to [ADDRESS_544480] transplant ;  
- Abnormal  PTT and INR values during prophylactic anticoagulation . 
   
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
____________________________ _ _ _ _ _ _ _ _ _ _
___________________________ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 41 of 68 
 
9. STATISTICAL ISSUES  
9.1. SAMPLE SIZE  
The primary efficacy endpoint of the clinical trial will be the proportion of insulin-independent 
patients following IAT over the time frame: day 365 +[ADDRESS_544481] ical significance for this endpoint will be achieved if the 
Pearson Chi -Square Statistic yields a two sided p -value less than 0.05.  The corresponding false 
positive error rate is (one -sided) 0.025.  In addition, 95% confidence interval for the difference of 
success (failure) rates between the reparixin and placebo groups will be provided, based on the normal distribution approximation to the standardized difference in estimated success rates . 
Based on published data from a retrospective series ( Sutherland, 2012 ), it appe
 ars that the likelihood 
of achieving insulin independence at 12 month follow -up in the placebo control arm  depends upon the 
number of IEQ /kg, with patients categorized in three groups: 
• < 2500 IEQ/kg: 13% i nsulin independence  
• 2500- 5000 IEQ/kg : 23% insul in independence  
• > 5000 IEQ/kg: 55% insulin independence  
In ther overal l ser
ies, the yields  were <2500 IEQ/kg  in 36%, 2500- 5000 IEQ/kg in 39% and > 5000 
IEQ/kg  in 24% of patients .  In the more recent series of 217 patient s receiving IAT from 2006 to 2011, 
corresponding yields were <2500 IEQ/kg  in 34%, 2500- 5000 IEQ/kg  in 42% and > 5000 IEQ/kg  in 
24%:  
We initially focus on t he cohort that i s in the range 2500- 5000 IEQ/kg, since these participants will be 
the largest fraction of enrollees.  It is anticipated that the percentage of such patients achieving insulin 
independence will be increased from 23% in the placebo control arm to 55% in the reparixin arm.  
Using standard statistical formulas based on the approximation of the binomial distribution by [CONTACT_430444], the sample size of 44 patients per arm provides 90% power to detect a 23% vs. 
55% true difference when using a Pearson Chi-Square Statistic having the traditional (one- sided) 2.5% 
false positive error rate. Even accounting for th e discreteness, the power should be in the 87%-90% 
range.   Furthermore, with 44 patients per arm, statistical significance (i.e., one- sided p=0.025) will be 
obtained if the estimated difference is 22.7% (10/44 ) vs. 43.2% (1 9/44), which is an estimated 20.5% 
increase in patients achieving insulin independence.  Hence, with [ADDRESS_544482] percentage of patients wil l be in the cohort  receiving IEQ/kg in the range 
2500- 5000 IEQ/kg, the trial will also enroll participants in two additional strata: <2500 IEQ/kg and 
>5000 IEQ/kg.  As noted above, we are presuming the middle strata would have an increase from 23% 
to 55 % in percentage of pa tients achieving insulin independence. This is an odds ratio higher than 4.  
If we have an odds ratio of approximately 4.3 to 4.5 in the other 2 strata and if approximately ½ of the 
patients would be from the 2500-5000 IEQ/kg  stratum, then only a modest increase of about 12 
additional patients beyond the 88 patient sample size would be needed to maintain the statistical power 
of the trial.  An increase in success rate from 13% to 40% in the <2500 IEQ/kg  stratum  would be an 
odd ration of 4.4 and an increase in success rate from 55% to 84% in the >5000 IEQ/kg  stratum  would 
be an odd ration of 4.3.  
Based on these considerations, it is planned to enroll 100 patients in this t rial who receive IAT, with 
the expectation that there will be approximately 5 others wh o do not receive IAT.  Under such a plan, 
the trial would not be overpowered even i f all participants were in the 2500 -5000 IEQ/kg stratum since  
statistical significance (i.e., one- sided p=0.025) would be obtained with 52 patients per arm if the 
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _ _
___________________________________________________
___________________________ _ _ _ _ _ _ _ _ _
___________________________ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 42 of 68 
 
estimated difference is 23.1% (1 2/52) vs. 4 2.3% (22/ 52), which is an estimated clinically significant 
19.2% increase in percentage of patients achieving insulin independence.  
The sample size of 100 to 105 patients also provides high statistical power for the key secondary 
endpoint, C -peptide AUC (MMT T) normalized by [CONTACT_430445]/kg.  Based on  preliminary data reported from 
the ongoing pi[INVESTIGATOR_4251] (see table on page 14), month [ADDRESS_544483] deviations 
for this endpoint are 1.92+1.62 in the reparixin group and 0.44+0.[ADDRESS_544484] greater than 95% power to detect a difference in 
means of at least 1.48 (the difference between a treated mean of 1.92 and a control mean of 0.44) 
assuming  that the common standard deviation is 1.37 and using an 0.00 25 two-sided significance 
level.  
9.2. RANDOMIZATION 
Patient will be randomized in a 1:[ADDRESS_544485] will be generated with a computer procedure by [CONTACT_430446] i
n which treatment (in blocks of 4) will be balanced within centres.  A master 
randomization list will be generated, randomizing an excess of patients (a maximum of 40 for each site – additional 8 patients for the site of the Primary Investigator ) to allow competitive recruitment 
within each centre.    
The randomization list will be prepared by [CONTACT_430447]é in a 
sealed envelope 
to prevent unblinding.   
Similarly, individual  treatment  codes wil l be provided as a tamper -resistant system ( either a sealed 
envelope or a scratch card ).  Such system will definite allow to recognize if the code has been broken 
and guarantees detection of any code misuse. Individual treatment codes will be pro vided to:  
- the Pharmacist (or designee) within each participating site for Investigational Product preparation;  
- the Dompé Pharm
acovigilance department for safety procedures.  
The Investigato
rs can request to an independent facility (either by [CONTACT_430426]) an  
individual code  in the event of an emergency only, where knowledge of the blinded treatment for that 
patient could influence further patient care.  Any potential unauthorized code break and the reason 
behind it will be recorded. 
The randomization codes will also be access ible to an Independent S tatistician (liaison between the 
CRO database and DMC Biostatistician) who will generate the reports for the Data Monitoring 
Committee (DMC ) evaluation (see  Section 12.5). 
The randomization code will be broken at study completion, i.e. when the last patient has completed 
his/her last follo
w-up visit (planned 365 days after islet infusion), and once  the database has been 
locked.  
9.3. ANALYSIS POPULATION 
The Intent to Treat (ITT) population will cons ist of all patients who are randomized and receive the 
Investigational Product (either reparixin or placebo); it  will be based on the treatment randomized, 
regardless of the treatment actually received.   Patients will be in the ITT analysis whether or not they 
receive IAT, because exclusions cannot be made for events occurring after randomization that could be influenced by [CONTACT_430421].   The primary and secondary efficacy analyses will be 
presented primarily for the ITT Population. 
Version No. 2 – final 18Jul [ADDRESS_544486] of all  randomized patients and will be based on the treatment 
actually received.  The Safety population will be used to present the demographic and baseline data, 
and all safety data.  
9.4. STATISTICAL METHODOLOGY  
All patient data collec ted on the CRF and on the Diary will be listed by [CONTACT_4676], treatment group and 
centre.   
Appropriate descriptive statistics will be produced, according to the variable.  For continuous 
variables, the data w
ill be presented according to a clinically relevan t discretization .  For categorical 
data, frequencies and percentages will be presented.  If appropriate, confidence intervals around the mean or the proportions will be presented.  
All the AUC analyses will be based on actual rather than scheduled timings and will be calculated 
using the trapezoi
dal rule.  If the actual time is not recorded, the scheduled time will be used instead.  
For ease of interpretation, the AUC value obtained will be divided by [CONTACT_430448].  
The data will be presented in the Clinical Study Report.  A Statistical Analysis Plan will be issued describing detai
ls of all the statistical methods and analyse s to be applied to trial results , including 
alpha spending and testing for multiple endpo ints.  Any deviations from the original statistical plan 
will be described in the C linical Study Report. 
All reasonable efforts will be made to prevent missing data.  Thoughtful methods for imputation of 
missing data will 
be presented in the Statistical An alysis Plan for the clinical trial  
9.4.1. Demographic and baseline characteristics  
Demographic and baseline characteristics will be summarized for all patients in the Safety population, 
by [CONTACT_1570]. 
9.4.2. Primary and Secondary Endpoint analysis 
For the primary e fficacy endpoint, the proportion of insulin- independent patients over the time frame 
of day 365+ 14 after the transplant, the differences in proportions will be assessed using the Pearson 
Chi-square statistic, stratified by [CONTACT_430409]: < 2 500 IEQ/kg vs. 2500- 5000 IEQ/kg 
vs. > 5000 IEQ/kg .  The significance level used for statistical testing will be 2.5% and one- sided test 
will be used .  The 95% confidence interval for treatment proportions and for the difference in 
treatment proportion between repa rixin and placebo will be produced .  The primary analysis will be 
performed using
 both ITT population with PP analysis serving as a sensitivity analysis.  
For secondary endpoints that will be tested both at 75±14 and 365±14 days after the transplant, only the day 365±14 time poi
nt will be tested for superiority in the fixed sequence testing procedure.  
The C -peptide AUC after the MMTT normalized by [CONTACT_430445]/kg will be analyzed at the two time  points by 
a repeated measurement
s model using PROC MIXED within SAS®, including terms for treatment , 
time point and center.  T he treatment effect within each time point  will be compared using a two- sided  
test at the 5%  lev
el.  The estimated treatment difference between reparixin and placebo at each time 
point will be p resent
ed together with the corresponding 95% confidence interval.  The confidence 
interval will be generated using α=0.05.  
The mean in average daily insulin requirements at the two time points will be analyzed using a 
repeated measuremen
ts model using PROC  MIXED within SAS®.  The model will include fixed effect 
Version No. 2 – final 18Jul [ADDRESS_544487] at the 5% level.  
The proportion of patients with an HbA1c <6.5% will be analyzed at day 365+14.  Additionally, the 
proportion of patients with an HbA1c <6.5% at day 365+14 will be analyzed  again , but patients are 
included in this second analysis if they are also free of severe hypoglycemic events from day 75 +14 to 
day 365+[ADDRESS_544488] sandwich- type variance estimate.  
The other secondary efficacy endpoints  will be analysed usin g appropriate parametric and non -
parametric tests and appropriate 95% CI will be presented.  
9.4.3. Safety analysis 
Safety variables will be presented fo r the Safety population, by [CONTACT_1570].  
All AEs will be coded using the most up- to-date version at t he time of database lock of the MedDRA 
and will be presented by [CONTACT_168322].  AEs will be presented in terms of the incidence, severity and relationship to the study drug, overall and by [CONTACT_430449].  SAEs will be presented in the same way.  
Results for laboratory test  at screening and ho
 spi[INVESTIGATOR_430387] -significant outside results .  The following 
parameters will be also presented at different time points:  AST/ALT, INR/PTT, fibrin degradation 
products (XDPs), C -reactive protein (CRP) will be presented for all da ily from day 1 up to day 7 after 
transplant and on day 75+ [ADDRESS_544489]/ALT.  Serum level of albumin and pre-albumin 
will be summarized as absolute values and change from pre -transplant value at day 75 +14 and 365+ 14 
after transplant.    
Vital signs at each time point  and the change in vital signs from pre-transplant value, and weight loss 
will be presented using descriptive statistics.   
Steatorrhea and malnutrition risk will be graded as described i n 4.2.3.  Analysis will be performed 
separately  at day 75+ 14 and 365+ 14 after transplant. 2x4 contingency table will be performed at each 
time point. 95% confidence intervals of proportion will be also done . 
Analysis of documented hypoglycemia epi[INVESTIGATOR_430388] -related events, recorded  as 
cumulative number of epi[INVESTIGATOR_302054], will be performed from  day 75+14 to 365+ 14 after islet 
infusion. Mean, median, SD, min, max will be calculated  for the interval  
9.4.4. Analysis of exploratory endpoints 
Chemokines/cytokines will be presented using appropriate descriptive statistics, by [CONTACT_1570] . 
The relationship between inflammatory chemokines/cytokines response and exposure  to reparixin  will 
be exp
lored. 
Serum level of miR -375 will be presented  using appropriate descriptive statistics, by [CONTACT_12922]. 
The comparison will be made between the reparixin and the placebo control arms regarding the rates 
of patients who are 
randomized but do not receive IAT. 
Version No. 2 – final 18Jul [ADDRESS_544490] more limited utility in this setting. 
The DMC will give careful considerati on to the appropria
 teness of trial continuation if there is 
emerging evidence that Reparixin is harmful.  One component of this assessment will be the rate of 
unexpected deaths.  Based on historical experiences from the published Minnesota series for 1977-
2011 that includes 356 adults, 217 underwent pancreatectomy and IAT from 2006- 2011. There was 1 
unexpected death within 12 months of transplant.  This translates to an estimated 0.5% rate. 
The DMC will consider the following guidelines regarding early termination based on the occurrence 
of unexpected deaths.  E
arly termination will be considered if: 
• there are at least [ADDRESS_544491] 33 r eparixin patient s (an outcome with 1.2% 
chance if the true event rate is 0.5%);  
• there are at least 3 unexpected deaths in reparixin patient s at any time in the trial (an outcome 
with 0.2% chance in 50 reparixin patients if the true event rate is 0.5%).  
In making any recommendations about termination, the totality of data will be considered, including 
the num ber of unexpect
ed deaths in the control group, and the available evidence about efficacy and 
the overall safety profile.  
The DMC will also give particula r attention to clinically significant coagulation abnormalities, 
including but not limited to intra -abdominal or gastrointestinal hemorrhage.  Early termination would 
be considered if  the rate of clinically significant post -surgical complications that require reoperation  
reliably exceeds the rate expected currently in standard practice settings.   Insights about that rate in 
standard practice settings will be provided by a literature review, and will include the publication for  
the Minnesota series,  where  intra -abdominal as well as gastrointestinal hemorrhage have been reported 
to be the most common reasons for reoperation ( Sutherland, 2012 ). 
The DMC will also consider early termination if the quality of conduct of the trial is such that the trial 
will not be able
 to provide a timely and reliable answer to the questions it was designed to address. 
9.4.6. Missing da ta 
All reasonable efforts will be made to reduce the rate of missing data, since any method used for imputation for missing observations would be based on untestable assumptions that likely would be 
invalid.  
Investigators will be trained about the importan ce of patient reten
 tion and full data capture.  Also, any 
reasonable attempts should be made by [CONTACT_430450]’s participation for the full duration of the trial  (see details in Section 7.3.1 and 10.2).  Howe ver, in order 
to minimize missing data, if a patient cannot refer to the site for a planned follow -up visit, the 
Inve 
stigator will try to obtain any relevant information from the patients, including 
documents/laboratory results available from local medical care.  
Subject s who die before the primary endpoint assessment at [ADDRESS_544492] to follow -up by 12 
Version No. 2 – final 18Jul [ADDRESS_544493] to follow-up will be very small .   
9.4.7. Methods for multiplicity correction in analyses  
If the primary analysis of the primary endpoint leads to rejection of the null hypothesis, the null 
hypotheses for the secondary endpoints will be tested in a conditional sequential manner.   A null 
hypothesiswill be rejected if and only if the primary analysis of that endpoint and all primary analyses of preceding  primary and secondary endpoints result in a rejection of the respective null hypotheses. 
This procedure protects the family -wise false positive error rate at the overall one- sided 0.025 level . 
It is noted that for secondary endpoints that will be tested both at 75±14 and 365±14 days after the transplant, only
 the day 365±14 time point will be tested for superiority in the fixed sequence testing 
procedure.  
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
___________________________________________________
___________________________ _ _ _ _ _ _ _ _ _
___________________________ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 47 of 68 
 
10. ETHICAL CONSIDERATIO NS 
10.1. INSTITUTE REVIEW BOAR D (IRB) 
It is the responsibility of the Investigator to obtain approval of the trial protocol/amendments from the 
appropriate IRB. 
Prior to the initiation of the study, the followings will be submitted to the IRB  for approval: 
• the study
 protocol, 
• the Patient Informed Consent Document, 
• the current version of the I nvestigator’s Bro chure,  
• Investigator’s current curriculum vitae,  
• any other requested document(s). 
A copy of the IRB a
pproval will be sent to Dompé along with all other correspondence with the IRB, 
including the submission documents.  The Investigator shoul d file copi[INVESTIGATOR_430389].   
The study will not be started until full written approval has been obtained from the appropriate IRB.  
The letter of appr
oval should be dated, and should specify the type (e.g. protocol number) and the date 
of the documents which were reviewed and approved.   
The Investigator will submit any future amendment to the protocol to the IRB which granted the 
original approval.  Any amendment will be implemented only when full approv al has been obtained 
from the appropriate IRB, except for those amendments which involve only logistical or 
administrative aspects of the study.  
The Investigator will send to the IRB a ny updated Investigator’s Brochure received from Dompé (or 
designee) . 
The Investigator will submit required progress reports to the IRB which approved the protocol at least 
annually, as well as report any serious ADRs, life-threatening problems or deaths.   
The Investigator will also inform the IRB of reports of seri ous ADRs o ccurred at other sites 
participating to this clinical trial and/or in other clinical studies conducted with reparixin.   The Investigator must inform the IRB of the terminati
 on of the study. 
10.2. INFORMED CONSENT  
No study -related procedures (including non- invas ive and diagnostic procedures) will be undertaken 
prior to completion of the consenting process.   Each potentially eligible patien t will be informe
 d of the study’ s objectives and overall requirements.  
The Investigator will explain the study fully to him/her using the Patient Informed Consent Document  
(PI[CONTACT_398] ).  Although patients will be informed that they can withdraw consent at any time, the 
Investigator will also emphasize that missing data diminish the scientific value of all patients’ 
contributions.  If  the patient is willing to participate in the study, (s)he will be requested to give written 
informed consent after being given sufficient time to consider his/her participation and the opportunity to ask for further details.    
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
___________________________________________________
___________________________ _ _ _ _ _ _ _ _ _
___________________________ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 48 of 68 
 
The PI[INVESTIGATOR_430390].  Although 
nursing staff may be involved in describing the trial to a patient, the Principal Investigator (or a Sub-
Investigator) must participate in discussions with the patient  and sign and personally date the PI[CONTACT_398] . 
A copy of the signed form will be provided to the patient, and the original signed PI[INVESTIGATOR_430391].  Patient consent will be documented in the hospi[INVESTIGATOR_2553].  
Individual (i.e. site specifi c) PI[INVESTIGATOR_430392] a master document provided by [CONTACT_58231]é  and must 
be approved by [CONTACT_58231]é prior to submission to the IRB.  Any changes requested by [CONTACT_430451]é prior to the documents being used.  Translation into a language different  from 
English will be provided, if required.   
10.3. CONFIDENTIALITY  
All information obtained during the conduct of the study will be regarded as confidential.  An 
agreement for disclosure will be obtained in writing by [CONTACT_430452] P ICD.  
Patient’s data collected during the study will be handled in accordance with applicable data protection 
laws and regulations.   The patient’s privacy associated with the use and disclosure of the patient’s 
protected health information will be safeguard ed under applicable country laws (e.g. H IPAA ). 
On the CRFs or Diary Cards , patients will be identified ONLY by [CONTACT_16790].  If 
patient names are included on copi[INVESTIGATOR_317846]é (or to the CRO appointed by 
[CONTACT_58231]é) , the names will be obliterated or masked and the assigned patient number added to the 
document. 
The Investigator should keep a separate log ( Patient Master L ist) of patient’ s codes, names and 
addresses.  
10.4. COMPENSATION FOR MEDICINE -INDUCED INJURY AND 
INDEMNIFICATION  
Before the trial formally starts, Dompé will take out a study- specific insurance contract covering the 
amount requested by [CONTACT_430453]/Investigators/Institutions  participating in 
the clinical trial.   
In case of questions about medical care, cost for medical care or insurance, patients can talk to their 
Investigator. 
 Contact [CONTACT_430454] P ICD. 
Insurance and any updates will be provided to the Investigator before trial commencement for filing into the  Investigat o 
r Site File .  
Version No. 2 – final 18Jul [ADDRESS_544494] parties, except for authorized Dom pé’designee or 
representatives of appropriate Health/Regulatory Authorities, without written permission from Dompé. 
A CRF is required and should be completed for each included patient.  The Investigator will be 
responsible for the accuracy of t
he data ente red in the CRFs.  All entries must be written in ENGLISH  
in black ink.  Source documents should be available to support all the data recorded in the CRF.  
The CRF must be available for review/collection to designated Dompé’s representatives at each 
schedul ed monitoring visit.  
11.2. DIARY CARD  
Diary Cards will be supplied by [CONTACT_430455]é .  They are the sole property of Dompé 
and should not be made available in any form to third parties, except for authorized Dompé’designee or representatives of appr opriate Health/Regulatory Authorities, without written permission from 
Dompé. 
A sample Diary Cards is provided in Appendix 14.[ADDRESS_544495] pages for all patients wi ll be data- entered (double data entry) into the study 
database, and the data will be verified for missing data, inconsistencies, and for any necessary medical 
clarifications.   Queries arising from these checks will be sent to the Investigator for response and 
signature.     
Once all data queries have been resolved, the study will be declared to be “clean”, and the study data 
will be locked ready for analysis.   
Af
ter the database lock has been achieved, the Investigato r may archive the copi[INVESTIGATOR_430393]
y Card retained at the centre.  The original CRF  and Diary  Card  collected by [CONTACT_430456]é will be transferred to  Dompé for archiving.  
11.4. DOCUMENTATION REQUIRED PRIOR TO INITIATI ON OF AND 
DURING THE STUDY 
In addition to the documents mentioned in Sections  10.1 and 12.1, the following will be required from 
the Investigator prior to the initiat
ion visit:  
• Current, sign ed and dated Curriculum Vitae, GCP quali fication, and Financial Disclosure 
Statement  of Principal Investigator [INVESTIGATOR_219793]- Investigators .  Updates should be provided at lest 
every two years.  
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
___________________________________________________
___________________________ _ _ _ _ _ _ _ _ _
___________________________ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 50 of 68 
 
• Normal ranges of all laboratory tests to be performed at the study site and a recent certification or 
accreditation of established quality control (or other documentation of established quality control or external quality assessment or other validation).  Updates should be provided as soon as any 
reference value has cha nged. 
• A signed page  of the final pr
 otocol and any amendments . 
• A signed original of the study Financial Agreement/Clinical Study Agreement with Dompé , 
including Pharma
cy, laboratory etc (i.e. all study specific costs). 
• List and any updates of delegated resp onsibility ( Study Team Signature [CONTACT_46979] / Delegation of 
Responsibilities form).  
• Form 1572 and financial disclosure form 3455 from all the persons listed on the 1572. 
11.5. ESSENTIAL DOCUMENT RETENTION  
The Investigator will retain copi[INVESTIGATOR_285421] (as defined by [CONTACT_12212]- GCP) until at 
least [ADDRESS_544496]: the signed protocol, copi[INVESTIGATOR_87297],  and 
Diary Cards,  sig
ned Patient Informed Consent Forms from all patients who consented, hospi[INVESTIGATOR_430394], and all other documentation included in the Investigator Site File and 
Pharmacy/Dispensing File.  
The Investigator will inform Dompé of the storage l ocation of these essential documents and must 
contact [CONTACT_58231]é before disposing of any.  If the I nvestigator wishes to assign the files to someone else 
or to remove them to another location, he/she should consult with Dompé about this change. Dompé will inform the Investigator in writing when these documents no longer need to be retained. 
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
___________________________________________________
___________________________ _ _ _ _ _ _ _ _ _
___________________________ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 51 of 68 
 
12. STUDY MANAGE MENT  
The study will be performed in accordance with the protocol, the Declaration of Helsinki  (59th WMA 
General Assembly, Seoul, October 2008) and ICH Harmonised Tripartite Guideline for Good Clinical 
Practice (ICH -GCP ) and any local regulations. 
12.1. REGULATORY BODY APPROVAL  
The study will not be started until review  from FDA has been positively completed . 
12.2. STAFF INFORMATION & RESPONSIBILITIES  
It is the responsibility of the Investigator to ensure that all personnel involved in the study are fully informed of all relevant aspects of the study, including detailed knowledge of and training in all 
procedures to be followed. 
The Investigator will provide a list of delegated responsibility t
 o the CRO appointed by [CONTACT_58231]é  
detailing the various study tasks to be performed by [CONTACT_285488]/her study staff.  Each staff 
member should sign in agreement to their performing each of the tasks delegated to them on the list. 
12.3. MONITORING  
Monitoring will be carried out by [CONTACT_430457]é.  
Prior to study start,  the Investigator will be informed of the anticipated frequency of the monitoring 
visits.  (S)He  will also receive a notification prior to each monitoring visit during the course of the 
study.  It is expected that the Investigator and/or his/her sub -Invest igator(s) and other appropriate staff 
will be available on the day of the visit to discuss study conduct and to cooperate with the monitor to 
ensure that any problems detected during the course of these monitoring visits are resolved.  
The purpose of the monitoring visit is to verify that the rights and the wellbeing of the patient are protected, that the
 reported data are accurate, complete and verifiable from source documents and that 
the conduct of the trial complies with the currently approved protocol and any amendments, with ICH 
GCP, and with regulatory requirements.  
Monitoring at the P harmacy will be car ried out by [CONTACT_941] U- CRA in order to maintain study blind with all 
other CRO/site st aff involved. 
12.3.1. Access to records  
The Investigator will allow designate d Dompé representatives and regulatory bodies to have direct 
access to the source documents to verify the data reported in the CRFs.  Source documents are the 
originals of any documents used by [CONTACT_192162][INVESTIGATOR_307]/institution that allow verification of the 
existence of the patient and substantiate the integrity of the data collected during the trial.  Source 
documents should be available to support all the data recorded in the CRF.  Location of source data, 
including those for which the CRF might be accepted as being the sole source document, will be 
specified and listed at the centre  Initiation Visit.    
12.4. AUDIT AND INSPECTION 
Audit activities will be performed by [CONTACT_430458]é , except 
for audit to Protocol/Amendments, Patient Informed Consent Document (template) and CRF that will 
be done by [CONTACT_395849]é Quality Assurance Unit.  
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
___________________________________________________
___________________________ _ _ _ _ _ _ _ _ _
___________________________ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 52 of 68 
 
On one or more occasions the study site may be audited by [CONTACT_430455]é. The 
Investigator will be informed in advance of such a visit.   
Additionally the study site may be inspected by a regulatory agency on one or more occasions. 
12.5. DATA MONITORING COMM ITTEE  
An independent Data Monitoring Committee (DMC ) will be established  and will be responsible for 
safeguarding the in
terests of t rial participants,  and for enhancing the integrity and credibility of the 
trial. The DMC will assess the safety and efficacy of the interventions during the trial, and will 
monitor the overall conduct of the clinical trial.  The DMC will provide recommendations  to Dompé  
about stoppi[INVESTIGATOR_430395].  To contribute to enhancing the integrity of the trial, the DMC 
may also formulate recommendations  to Dompé  relating to the selection/recruitment/retention of 
participants, t
heir management, improving adherence to protocol -specified regimens and retention of 
participants, and the procedures for data management and quality control. 
The D MC will operate independen tly of Dompé, and its members will not have connections to Dompé 
with the exception of the co mpensation to D MC members related to their activities.  
The D MC will comprise thr ee members. They will be a multidisciplinary group that will include:  
• Two surgeon s/physicians with e xtensive experience in islet transplantation and critical care 
medicine (e. g. a. Medical Director of a Transplant Program); 
• A Biostatistician  with substantial experience in the DMC process. 
The D MC: 
• Will review unblinde
d data. To this purpose, an Independent Statistician will lia ise with the CRO 
statisti
cian and will have access to those components of the database necessary to generate the 
reports to the DMC. 
• Will be responsible for the ongoing (at least every 4 months) review of safety data throughout the 
trial.  Primary among 
the safety data that will be reviewed are Serious AEs. In particular, t he 
DMC  will monitor the number of deaths for both arms of the study to assess whether  mortality is 
consistent with historical data. The DMC also will give attention to post -surgical reoperation and 
clinically significant coagulation abnor malities  (intra-abdominal as well as gastrointestinal 
hemorrhage have been reported to be the most common reasons for reoperation ). 
• Will review  efficacy  data in an ongo ing manner to enable the assessment of the acceptability of 
safety in the context of emerging evidence about  efficacy, i.e. measures of metabolic control and 
graft function.   
• Will be advisory to Dompé and make recommendations to  Dompé regarding t he continuation of 
the trial and potential modifications to the design and conduct of the trial.  These 
recommendations will be made in a manner to maintain confidentiality of emerging information 
about efficacy and safety, unless access to certain data is needed to enable Dompé to make 
decisions about the DMC recommendations.   Dompé will be responsib le for promptly reviewing 
the DMC recommendations, to decide whether to continue or terminate the trial, and to determine whether amendments to the protocol or changes in the study conduct are required  
All details of the conduct and responsibilities of the DMC will comply with Guidan
 ce for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees  and will 
be described in the ‘DMC Charter’ to be finalized during the set-up phase of the study and prior to the 
initiation  of enrollment . 
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
___________________________________________________
___________________________ _ _ _ _ _ _ _ _ _
___________________________ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 53 of 68 
 
12.6. PROTOCOL DEVIATIONS/AMENDMENTS  
Changes to the Protocol will be implemented only when written amendments have been signed by [CONTACT_430459].   
Any amendment will be sent to the appropriate  IRB.  No deviations  from or  changes to the protocol 
will be implemented without documented approval of an amendment from the IRB which granted the 
original approval, except where necessary to eliminate an immediate hazard(s) to trial patient, or when 
the change(s) involves only logi stical or administrative aspects of the trial.  The deviations from or 
changes to the protocol implemented to eliminate an immediate hazard to the trial patient and the proposed amendment, if appropriate, should be submitted to the IRB for review and approval as soon 
as possible.  
Any other deviation from the protocol that has not been approved by [CONTACT_58231]é and the IRB could resu
 lt 
in a discontinuation from the study at the centre  involved. 
Any written amendment will be sent to all recipi[INVESTIGATOR_430396] d to the Competent Authorities . 
12.7. DISCONTINUATION OF THE STUDY 
Dompé reserves the right to stop the study at any time on the basis of new information regarding safety or efficacy, or if study progress is unsatisfactory, or for other valid administrative reas ons.  
After such a decision is made, the Investigator must inform all relevant persons e.g. study staff, potential patien
ts etc. within [ADDRESS_544497] be collected and all CRFs 
completed to the extent possible.  
Study discontinuation will be notified to the FDA within 5 days from decision. 
12.8. PUBLICATIONS  
As this study is part of a multicentre trial, publications derived from this study will be planned and 
agreed with the participating Investigators.  Publications will include input from the Investigators, 
his/her colleagues, other investigators in this trial and Dompé personnel.  Such input will be reflected 
in publication authorship.  Criteria for selection of authors will be agreed.  Subsequent to the 
multicentre publication or o ne year after completion of the study, whichever occurs first, an 
Investigator and/or his/her colleagues may publish the results of Investigator’s part of the study 
independently.  
Any manuscript, abstract or other publication or presentation of results or  information aris ing in 
connection with the study must be prepared in conjunction with Dompé and must be submitted to the 
Dompé for review and comment at least [ADDRESS_544498]. 
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
___________________________________________________
___________________________ _ _ _ _ _ _ _ _ _
___________________________ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 54 of 68 
 
13. REFERENCES  
Allegretti M et al . 2-Arylpropi[INVESTIGATOR_430397] 1 (CXCR1) ligands as novel noncompetitive 
CXCL8 inhibit
ors. J Med Chem 2005; 48:4312- 4331.  
American Diabetes Associacion. Defining and reporting hypoglycemia in diabetes. Diabetes care 2005; 28:1245-
1249. 
Balzano et  al. Auto
logous pancreatic islet transplantaiton (IAT) as endocrine tissue rescue in patients undergoing 
complete pamcreat
ectomy because of surgical complicaiton after W hipple resection.  Transplant Int 2011; 
abstract O -174 page 49.  
Bars
hes NR et al. Transa minitis after pan creatic islet transplantation. J Am Coll Surg 2005; 200:353 -361. 
Berney T et al. Long -term metabolic results after pancreatic resection for severe chronic pancr eatitis. Arc Sur 
2000 ; 135: 1106  
Bernstein L et al. Measurement of visceral pro tein status in ass essing protein and energy malnutrition: standard 
of care. Prealbumin in Nutritional Care Consensus Group. Nutrition 1995; 11:170 . 
Bertini R et al. Non -competitive allos teric inhibitors of the inflammatory chemokine receptors CXCR1 and 
CXC R2: prevention of reperfusion injury. PNAS 2004; 101:[ZIP_CODE]- [ZIP_CODE].  
Caumo A et al. Trans
plant Estimated Function. Diabetes Care 2008; 31:301 -305. 
Cavalieri B et al
. Neutrophil recr uitment in the rep erfused -injured rat liver was effective ly attenuated by 
[CONTACT_430460], a novel allosteric non -competitive inhibitor of CXCL8 receptors: a therapeutic approach for the 
treatment of post -ischemic hepatic syndrome. Int J Immunopathol Pharmacol 2005; 18:475- 486. 
Citro A  et al. CXCR2 inhibition improves islet transplantation outcome. Transplant Int 2011; abstract O -053 
page 15.  
Citro A et al. CXCR1/[ADDRESS_544499] 2012a 
122:3647- 3651. 
Citro A
 et al. CXCR2/1 inhibition modulates diabetes induced by [CONTACT_430461] 
(MDL_STZ) injection in mouse. 2nd Joint AIDPIT and EPI[INVESTIGATOR_430398]. Igls/Innsbruck 2012b, 
Abstract book, abstract PP -18 
Clinical safety data management: Definitions and Standards for Expedited Reporting (E2A - Approved b y the 
CPMP
 in November [ADDRESS_544500] June 1995 [Note for Guidance 3C614A]; Approved 
by [CONTACT_430462] 1st March 1995 [60 FR [ZIP_CODE]]).  
Cockcroft DW, Gault MH. Prediction of creatinine clearance from seru m creatinine. Nephron 1976; 16:31- 41. 
Cugini D et al. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to 
ischemia/r
eperfusion. Kidney Int 2005; 67:1753- 1761.  
Dong M et al. Systematic review and meta -analysis: isle t autotransplantation  after pancreatectomy for 
minimizing diabetes. Clin Endocrinol 2011; accepted article. 
Farley et al. Pancreatic resetion for ductal adenocarcinoma: total pancreatectomy versus partial pancreatectomy. 
Sem in Surg O
nc 1995; 11:124- 131. 
Garau A et al. Neuropr otection with the CXCL8 inhibitor repertaxin in transient brain ischemia. Cytokine 2005; 
30:125- 131. 
Garcea G et al. Total pancreatectomy with and without islet cell transplantation for chronic pancreatitis. Pancreas 2009; 38:1- 7. 
Version No. 2 – final 18Jul [ADDRESS_544501]. JPET 2007; 322:973- 981. 
Greenbaum MD et al. Mixed -Meal tolerance test  versus glucagon stimulation test for the assessment of β-cell 
function in therapeutic trials in type 1 diabetes. Diabetes Care 2008; 31:1966 -1971. 
Gruessner RWG et al. Transplant options for patients undergoing total pancreatectomy for chronic pancreatitis. J 
Am Coll Surg 
2004; 198:559- 567. 
Hogle  HH, Reemtsman K. Pancreatic autotransplantation following resection. Surgery 1978; 82:359- 360. 
ICH Harmon
ised Tripartite Guideline for Good Clinical Practice (June 1996), as recommended for adoption to 
the three regu
latory parties to ICH.  Approved on 17th July 1996 (CPMP/ICH/135/95). Approved by [CONTACT_3955] 9th 
May 1997 and effective 9th May 1997 (62 FR [ZIP_CODE]). Accepted  and published by [CONTACT_147121], 1997.  
Linehan et al. Total pancreatectomy for chronic pancreatitis. Gut 1988; 29:[ADDRESS_544502] et al. L
ong term outcome of islet autotransplantation following total pancreatectomy: the Leicester 
experience. Rev Diabetic Studies 2011; abstract O -[ADDRESS_544503] antation. Rev Diabetic 
Studies 2011; abst
ract P -227 page 182.  
Rafael E et al. Changes in liver enzymes after clinical islet transplantation. Transplantation 2003; 76:1280 -1284.  
REP0101 - Clinica
l study  ME0706; Dompé Internal Report (final).  
REP0102 - Clinical study  ME0735; Dompé Internal Report (final).  
REP0103 - Clinical stu dy M E0757; Dompé Internal Report (final).  
REP0203 - Clinical s tudy ME0761; Dompé  Internal Report ( final). 
REP0104 - Dompé Intern al Report (final) . 
REP0204 - Dompé Intern al Report (final) . 
REP0110 - Dompé Study P rotocol.  
Ryan EA et al. An assessment of β-cell function afte r islet transplantation. Diabetes Care 2005; 28:343 -347. 
Sarr MG et al. Total pancreatectomy: an objective evaluation analysis of its use in pancreatic cancer. 
Hepatogastroen
terology 1993; 40:418- 421. 
Souza DG  et al. Reparixin , a no vel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow 
intestinal ischemia and reperfusion injury. Br J Pharmacol 2004; 143:132 -142. 
Sutherland DER et al. Pancreatic islet cell transplantation. Surg Clin North Am 1978; 58:365 -382. 
Sutherland et al. Total pancreatectom y and islet a utotransplantationfor chronic pancreatitis. J Am Coll Surg       
2012; 214:409-424. 
Villa P et al. The Interleukin -8 (IL- 8/CXCL8) receptor inhibitor reparixin improves neurological deficits and 
reduces long -term inflammation in permanent and transient cerebral ischemia in rats. Mol Med 2007; 13:125 -
133. 
 
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
___________________________________________________
___________________________ _ _ _ _ _ _ _ _ _
___________________________ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 58 of 68 
 
14.2. APPENDIX 2 - PACKAGING AND LABELING DETAILS  
The template of l abel specimens is provided below.   
 
 
Specimen label for the REPARIXIN Vial  
 
 
STUDY REP0 112 Sponsor Dompé s p.a.; Via Campo di Pi[INVESTIGATOR_5829], L’Aquila – Italy 
 Phone: + 39 [PHONE_8937]  
 
REPARIXIN  
   
INVESTIGATOR : 
 
CONTAINS : 250 mL REPARIXIN  (33 mg/mL) CONCENTRATE FOR SOLUTION FOR I.V. INFUSION  
 BATCH No. EXPI[INVESTIGATOR_430399]/y
 yyy DO NOT STORE AT >30°C (86°F)  
  
 
DIRECTIONS: Transfer into an INFUSION BAG the content of the vial + 500 mL of 0.9% NaCl, according to 
procedures detailed in the “Instructions to the Pharmacy”.  
 
Caution: New Drug -Limited by [CONTACT_44505].  
 
 
 
 
Specimen label for  the PLACEBO Via l  
 
 
STUDY REP0 112 Sponsor Dompé s p.a.; Via Campo di Pi[INVESTIGATOR_5829], L’Aquila – Italy 
 Phone: + 39 [PHONE_8937]  
 
PLACEBO  
   
INVESTIGATOR : 
 
CONTAINS : 250 mL Physio logic salt solution (0.9% w/v sodium chloride)  
 BATCH No. EXPI[INVESTIGATOR_430399]/y
 yyy DO NOT STORE AT >30°C (86°F)  
  
 
DIRECTIONS: Transfer into an INFUSION  BAG the content of the vial + 500 mL of 0.9% NaCl, according to 
procedures detailed in the “Instructions to the Pharmacy”.  
 
Caution: New Drug -Limited by [CONTACT_44505] . 
 
 
 
 
 
 
   
 
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
___________________________________________________
___________________________ _ _ _ _ _ _ _ _ _
___________________________ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 59 of 68 
 
Specimen  label for Infusion Bag - “double tear off” label 
 
Each of the [ADDRESS_544504] identic al information as per specimem below.  
 
STUDY  REP0 112 Sponsor Dompé s p.a.; Via Campo di Pi[INVESTIGATOR_5829], L’Aquila – Italy 
 Phone: + 39 [PHONE_8937]  
PATIENT No.  □□□□      INFUSION BAG No.  □ 
 
INVESTIGATOR : 
  
CONTAINS : 750 mL OF REPARIXIN (11.00 mg/mL) or PLACEBO I.V. INJECTABLE DOSING SOLUTION  
 
PREPARED ON  |__|__|/|__|__|/|__|__|__|__|     |__|__| : |__|__|   
      dd      /      mm    /           yyyy                         h       :      min   
DO NOT STORE AT >30°C (86°F)   
USE BY  |__|__|/|__|__|/|__|__|__|__|     |__|__| : |__|__|   
      dd      /      mm    /           yyyy                         h       :      min  
  
DIRECTIONS:  Administer as a continuous i.v. infusion into a (high flow) central vein, by [CONTACT_248276]. 
Infusion will start approximately 12 hours (6 to 18) before islet infusion. Pump rate wil l be 
adjusted according to patient body weight as per Appendix 3 of Study Protocol.  
 
Caution: New Drug -Limited by [CONTACT_44505] . 
 
 
NOTE : Shadowed field are those to be completed by [CONTACT_430463].  
 
 Patient No. Report the four digit number derived from the “IP Preparation 
Order Form” received from the Investigator.  
  Infusion Bag No
. Report the sequential bag number within the series for that 
patient.  
  
 Preparation date/time  Report the date and time when the  preparation of the dosing 
solution has started.  
 
 Use by [CONTACT_568]/time  Calculate the use by [CONTACT_430464]/time of preparation + 
maximum 72 hours (expi[INVESTIGATOR_5695]/time of the dosing solution), 
unless the site has more restrictive rules for reconstituted 
solutions (e.g. 24 hours).  
 
Version No. 2 – final 18Jul [ADDRESS_544505]/Examination  HOSPI[INVESTIGATOR_430400] -UP 
 
Screening  day  
-1 day 0 
Tx day  day 1 day 2 day 3 day 4 day 5 day 6 day 7 Hospi[INVESTIGATOR_430401] e day 75 +[ADDRESS_544506] 
transplant  day 365 +[ADDRESS_544507] 
transplant  
Informed consent  X             
Inclusion/exclusion criteria  X             
BP, HR, weight, height1 X          X1 X1 X1 
Safety laboratory tests  X          X   
Pregnancy test  X             
Renal res erve/function2 & Total bilirubin X   X X X X X X     
Albumin and pre -albumin  X           X X 
Concurrent sepsis  X             
Pre-operative portal hypertension  X             
miR-375; Inflammatory chemokines/cytokines3 XX3 XXX3 X3  X3  X3  X3    
Study d rug administration4  X-----------------------------------------------------------------------------------X     
PK sampling4    X  X  X X4    
ALT/AST     X X X X X X X  X  
XDP, INR/PTT, CRP     X X X X X X X    
Average daily insulin; HbA1c             X X 
Severe, Documented Symptomatic, 
Asymptomatic hypergycemia events             X-----------------------------X 
MMTT5: Glucose, C -peptide, insulin             X X 
β-score – TEF calculation             X X 
Steatorrhea6 and malnutrituion risk6            X X 
Adverse Events   X-------------------------------------   Record all AEs up to each h ospi[INVESTIGATOR_430402], only SAEs   ------------------------------------X 
Concomitant M edication  X-------Record all CMEDs up to each hos pi[INVESTIGATOR_430402], only drugs used for SAEs, oral hypoglycemic drugs and forbidden medications -------X 
1 = Measure only BP and HR at hospi[INVESTIGATOR_2345]. Measure only weight at follow -up vis its.  
2 = Assess Creatinine clearance on pre-transplant. Assess creatinine clearance AND urine output from day [ADDRESS_544508]-transplant . 
3 = 
Store a serum sample for centralized assay as detailed in Appendix 14.6. 3. Take the 2 chemokines/cy tokines pre-tr ansplant sample s 6 to 24 hours apart; obtain all basal  samples before 
surgery and before the Investigational Product administration  is started.  Take post -transplant sample s @ 6, 12, 24, 72, 120 and 168hrs after islet infusion.  
4 = Start study drug infusion approximately 12 (6-18) hours before islet infusion.  Obtain PK ideally in th e morni ng (day 1, 3, [ADDRESS_544509]-transplant ). Obtain (if you are one of the 2 selected sites) a 
sample just prior to, and then 1, 3, 5, 6, 8, and 12 hours after  the end of study drug administration.   
5= Mixed Meal Tolerance Test: m easure glucose, C -peptide  and insulin prior to (2 basal samples in the range between -20 to 0 prior to the meal) AND @ 15, 30, 60, 90, 120, 180 and 240 min 
after the meal, as detailed in Appendix 14.6.4. Stor e a blood sample for centralized assay of C-peptide and HbA1c as detailed in Appendix 14.6. 3. 
6= Evaluate steatorrhea in t he 4 weeks preceeding  the follow -up visit. Evaluate malnutrition risk level as per pre -albumin value . 
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
Page 213 of 219
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
___________________________________________________
___________________________ _ _ _ _ _ _ _ _ _
___________________________ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 63 of 68 
 
14.5. APPENDIX 5 - ACCEPTABLE TIME WI NDOWS FOR ASSESSMENT S/ 
PROCEDURES  
 
Assessment/Procedure  Window  
Investigational Product administration 
Start of Investigational Product infusion @ 
12hrs prior to islet transplant.   6-18hrs prior to start of islet infusion 
End of Infusion @ 7 days (168hrs ). ± 12hrs  
Follow- up visits  
Visit @ day 75 and 365 after the transplant  ± [ADDRESS_544510]  
Sampling @ 15, 30, 60, 90 , 120, 180, 240  
mins after the meal  ± 5 mins (15 min and 30 min) or ± 10 mins  
(60 to 240  min)  
Chemokine /cytokines ; miR -375 
Sampling @ 6, 12, 24, 72, 120 and 168hrs after 
islet infusion  ± 10 mins  (6 to 24 hrs ) or ± 30 mins ( 72 to 
168hrs ) 
PK sampling   
Sampling on post -operative day 1, [ADDRESS_544511] administration  
Sampling @ 1, 3, 5, 6, 8, and [ADDRESS_544512] 
administration  ± 10 mins 
 
 
 
 
 
Version No. 2 – final 18Jul [ADDRESS_544513] microscope and grouped in classes 
according to the
ir size (islet diameter; µm).  IEQ will be derived from the islet number in each class 
integrated by a conversion factor, as detailed in the table below , where “n” is the number of islet in each 
class.  
Class  
[islet diameter range (µ m)] Conversion into 
IEQ  
[islets of 150 
µm diame ter] 
50-100 n / 6 
101-150 n / 1.5 
151-200 n x 1.7 
201-250 n x 3.5 
251-300 n x 6.3 
301-350 n x 10.4 
>350 n x 15.8 
 
14.6.2. Calculation of creatinine clearance  
Renal function will be evaluated by [CONTACT_36574] ( CLcr ), calculated by [CONTACT_430465] 
(Cockcroft -Gault, 1976) : 
Male: CLcr =  [140 - age (years)]  Weight (kg)   
Serum Creatinine (mmol / L)  815  
 
Female: CLcr =  [140 - age (years)]  Weight (kg)  
 0.85 Serum Creatinine (mmol / L)  815 
 
14.6.3. Handling of samples for centralized assays and assay methods 
Detailed instructions will be provided for preparation, storage and shipment of samples.  Tubes and labels 
for storage will be provided by [CONTACT_430455]é , along with storage and shipment tracking 
forms.   
Samples will be shipped  in appropriate pack age in dry ice (solid CO 2) to maintain frozen conditions.  All 
samples will be shipped on an ongoing basis during the trial , according to logistics .  However, samples 
from the last patient visits will be shipped as soon as possible to e nsure timely availability of results.   
Arrangements will be made with each centralized laboratory to provide appropriate procedures for receipt 
and analysis of t
he samples and , apart from PK analysis (see section “PK samples below”) , back-
communication of  the results to the sending site.  All s teps will be tracked  to ensure correct data reporting .  
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
___________________________________________________
___________________________ _ _ _ _ _ _ _ _ _
___________________________ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 65 of 68 
 
Once received from the centralized laboratory, each site will enter values pertaining to its patients in the 
corresponding CRF.  All samples will be destroyed a fter final study report has been issued or after the 
patient has withdrawn his/her consent.  
The centralized laboratory for the assay of C -Peptide, HbA1c and Inflammatory chemo kines/cytokines  will 
be: 
Northwest Lipid Metabolism an
d Diabetes Research Laborat ories  (Santica Marcovina, Ph.D., D.Sc. );  
University of Washington - [ADDRESS_544514] North; Seattle, WA [ZIP_CODE] - US. Phone: +001 (206) 685 
3331; [EMAIL_8193] .  The laboratory is certified by [CONTACT_430466] a ll the analyses are perform ed  
under  strict quality control.  Also, the laboratory participates in the National Glycohemoglobin 
Standardization Prog r
am (NGSP) and the method is yearly certified at the level of Laboratory [ADDRESS_544515] values.  
 The c entralized laboratory for the assay of miR -375 will be: 
Diabetes Research Institute, 
 β-cell Biology Unit  (Lorenzo Pi[INVESTIGATOR_77878], MD ); IRCCS Ospedale San Raffaele; 
1st floor, Lot Q L33 ; Via Olgettina, 60; [ZIP_CODE] Milan, Italy.  
 
The c entralized laboratory for the assay of PK samples will be:  
CDMO Department  (Gaetano D’Anniballe BSc), Quality Control Laboratory; Dompé s.p.a. - Via Campo di 
Pi[INVESTIGATOR_5829]; [ZIP_CODE] L’Aquila - Italy. Phone: [PHONE_8952];  e-mail: [EMAIL_8194]  
 C-peptide  
Blood samples will be kept at room temperature for at leas t 30 min to allow clotting.  They will then be 
centrifuged at 700 × g within one hour from sampling .  Cell free serum samples for each time- point will be 
aliquoted (at least 2 x 0.5mL aliquots) and stored between -70°C and -80 °C until shipment to the 
centr alized laboratory .  Determination of C -peptide levels will be  performed by a two site immuno -
enzymometeric assay using a Tosoh 2000 auto- analyzer (TOSOH, Biosciences, Inc., South San Francisco, 
CA).     
 HbA1c  
EDTA whole blood samples will be collected and at least 2 x 1 mL aliquots will be stored between -70°C 
and -80°C until shipment to the centralized laboratory.  Measurement of the relative proportion of 
hemoglobin subclasses and calculatio
n of the HbA1c levels are performed by a dedicated analyzer 
(TOSOH, Biosciences, Inc) using non- porous ion exchange high performance chromatography to achieve 
rapid and precise separation of stable HbA1c from other hemoglobin fractions.  
 Inflammatory chemokines/cytokine s  
Blood samples , obtained before ([ADDRESS_544516] es collected 6 to 24 hrs apart; both samples will be obtained 
before surgery and before Investigational Product administration  is started ) and 6, 12, 24, 72, 120 and 
168hrs after the end of islet infusion , will be immediately kept at 4°C, protected from th e light and 
centrifuged within 2 hrs at 700 × g at 4°C.  Cell free serum will be aliquoted (4 x 100µ L aliquots) and 
stored between -70°C and -80°C until shipment to the centralized laboratory and analysis.   
Starting from 25 µL of thawed serum the following chemoki nes/cytokines will be determined  by a m ultiplex 
technology that uses magnetic bead  sets (BioRad BioP lex instrument using a Human Cytokine Panel ; 
Millipore Inc., H CYTOMAG -60K) : CXCL8, CCL2 (MCP -1), CCL3, CCL4, CXCL10 (IP -10), IL -6, IL -10, 
INF-γ, TNF -α, and IL-1β.  Due to cross -reactivity with the Human Cytokine Panel (HCYTOMAG -60K), 
analysis of CXCL -9 (MIG) is performed on a BioRad BioPl ex system using  MILLIPLEX MAP Human 
Cytokine/Chemokine Magnetic Bead Panel III (Millipore, Inc., HCYP3MAG -63K ). 
 miR -375  
Blood samples , obtained before (one basal sample collected before surgery and before Investigational 
Product administration is started)  and 6, 12, 24, 72, 120 and 168hrs after the end of islet infusion , will be 
immediately kept at 4°C, protected from the light and centrifuged within 2 hrs at 700 × g at 4°C .  Cell free 
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
___________________________________________________
___________________________ _ _ _ _ _ _ _ _ _
___________________________ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 66 of 68 
 
serum samples for each time- point will be aliquoted (at least 2 x 300µ L aliquots) and stored between -70°C 
and -80°C until shipment to the centralized laboratory and analysis.   
Circulating miR -375 levels will be measur ed by [CONTACT_325200] (ddPCR) ; serum samples will be 
extracted with commercially available kits and the recovered miRNA fraction will be first reverse 
transcribed and then partitioned into approximately [ZIP_CODE] droplets using the droplet generator of the Bio-
Rad QX100 droplet digital PCR system.  After PCR amplification in a conventional thermal cycler, each  
individual droplet from each sample will be read and its fluorescent status assessed using the QX100 droplet reader.  The output of the QX100 reader will be analyzed using the QuantaLife 1.3 software . 
 PK samples
  
Blood samples will be taken into lithium  heparin monovettes and centrifuged ideally within 15 minutes at 
2500 x g at 4° C for 10 minutes.  If that is not possible then samples can be stored at room temperature for 
not more than 2 hours or at 4oC for not more than 24 hours before centrifugation.  Plasma will be aliquoted 
(2 x 1.5mL aliquots) and stored at a temperature in the range -20°C to -80°C into stopped tubes (glass or 
plastic), until shipment to the centralized analytical laboratory.   
Analaysis will be carried out within one year from sampli ng. i.e. before the study blind  i s broken. 
Therefore, a ll samples obtained  during the conduct of the trial will be sent to the centralized laboratory and 
analyzed in order to maintain the study blind.  Appropriate procedures will be implemented by [CONTACT_430467]; also, results will be released only after study blind has been 
broken. 
Analysis will be performed according to standardized and validated methods as per Good Laboratory Practices.   In particular, the following PK parameters will be determined:  
C
initial  Plasma concentration of reparixin  and metabolites (DF 2243Y and ibuprofen) just prior to the 
end of infusion; 
Cmax Maximum plasma concentration of reparixin  and metabolites; 
tmax Time of maximum plasma concentration reparixin  and metabolites ; 
λz Terminal phase rate constant of reparixin  and metabolites ; 
t½ Terminal half life of reparixin  and metabolites ; 
AUC 0-t Area under the plasma concentration- time curve from time zero (Cinitial) to time t (time of last 
quantifi able plasma concentration) of reparixin  and metabolites; 
AUC 0-∞ Area under the plasma concentration -time curve from time zero (Cinitial) to infinity of reparixin  
and metabolites 
Vz  Volume of distribution of reparixin  
CL             Clearance of rep arixin  
  
Data will be summar
ised in a separate report  that will be integra ted into the final study report.     
14.6.4. Mixed Meal Tolerance Test 
The MMTT will be performed on all patients possibly after an overnight fast, according to Greenbaum 
(2008 ).  The test will be  initiated before [ADDRESS_544517]  High Protein  will be used for the MMTT.   
Patients will be given 6mL/kg of Boost preparation up to a maximum of 360mL, to be drunk within 5 min.   
Blood samples for glucose
, C-peptide and insulin measurement  will be with drawn in basal  condition ( two 
samples in the range between -20 to 0 prior to the meal) and then @ 15, 30, 60, 90, 120, 180 and 240 min 
after the meal.  
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
___________________________________________________
___________________________ _ _ _ _ _ _ _ _ _
___________________________ _ _ _ _ _ _ _ _ _
____________________________________________________

Study REP0112  Reparixin in IAT  Page 67 of 68 
 
14.6.5. β-score calculation  
β-score  will be calculated on a 0 -8 scoring system (Ryan, 2005 ) which gi ves 0 -2 points each for glucose , 
HbA1c, stimulated C-peptide and insulin requirement, as per the table below.   
 
Components  Score 2  Score 1  Score 0  
Fasting (or bef ore breakfast)  plasma glucose  
(mg/dL OR mmol/L)  <99 
OR < 5.5 100 – 124 
OR 5.6-6.9 >125 
OR >7 .0 
HbA1c (%)  <6.1 6.2 – 6.9 >7.0 
Daily average (previous week) insulin 
(IU/kg/day)  --- 0.01 – 0.24 >0.25 
Stimulated C -peptide ( ng/mL )1 >0.9* 0.3 – 0.89 <0.3#  
1: C- peptide level in the blood sample taken 90 min after drinking the mixed meal. *: If fasting C -peptide i s 
>0.9 ng/mL, then the stimulated C -peptide level is assumed to be >0.9 ng/mL. #: If stimulated C -peptide i s 
<0. 3 ng/mL, then an overall score of 0 i s awarded  
Version No. 2 – final 18Jul 2016  CONFIDENTIAL  
Dompé 
Reparixin
REP0112 
Clinical Study Report Final
Confidential
 
__________________________ _ _ _ _ _ _ _ _ _ _ _
____________________________ _ _ _ _ _ _ _ _ _ _
___________________________________________________
___________________________ _ _ _ _ _ _ _ _ _
___________________________ _ _ _ _ _ _ _ _ _
____________________________________________________
